JPH036143B2 - - Google Patents
Info
- Publication number
- JPH036143B2 JPH036143B2 JP3535282A JP3535282A JPH036143B2 JP H036143 B2 JPH036143 B2 JP H036143B2 JP 3535282 A JP3535282 A JP 3535282A JP 3535282 A JP3535282 A JP 3535282A JP H036143 B2 JPH036143 B2 JP H036143B2
- Authority
- JP
- Japan
- Prior art keywords
- yield
- mol
- irνcm
- cdcl
- nmr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 150000003839 salts Chemical class 0.000 claims description 11
- 125000000217 alkyl group Chemical group 0.000 claims description 5
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 66
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 62
- -1 organic acid salts Chemical class 0.000 description 46
- 150000001875 compounds Chemical class 0.000 description 37
- 239000012230 colorless oil Substances 0.000 description 32
- 238000002844 melting Methods 0.000 description 31
- 230000008018 melting Effects 0.000 description 31
- 238000000921 elemental analysis Methods 0.000 description 26
- 239000013078 crystal Substances 0.000 description 25
- 238000004519 manufacturing process Methods 0.000 description 21
- SPRIJFSYERPPCB-UHFFFAOYSA-N 2-hexylthiomorpholine Chemical compound CCCCCCC1CNCCS1 SPRIJFSYERPPCB-UHFFFAOYSA-N 0.000 description 16
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 14
- 239000003921 oil Substances 0.000 description 13
- 239000000126 substance Substances 0.000 description 13
- 208000025865 Ulcer Diseases 0.000 description 9
- 231100000397 ulcer Toxicity 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 210000002784 stomach Anatomy 0.000 description 7
- XPBRQULQNAAEDL-UHFFFAOYSA-N 2-dodecylthiomorpholine Chemical compound CCCCCCCCCCCCC1CNCCS1 XPBRQULQNAAEDL-UHFFFAOYSA-N 0.000 description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- NTQYXUJLILNTFH-UHFFFAOYSA-N nonanoyl chloride Chemical compound CCCCCCCCC(Cl)=O NTQYXUJLILNTFH-UHFFFAOYSA-N 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- HXZKGBRIQVZZII-UHFFFAOYSA-N 2-decylthiomorpholine Chemical compound CCCCCCCCCCC1CNCCS1 HXZKGBRIQVZZII-UHFFFAOYSA-N 0.000 description 4
- LGCYWCUWQBYGDP-UHFFFAOYSA-N 2-octylthiomorpholine Chemical compound CCCCCCCCC1CNCCS1 LGCYWCUWQBYGDP-UHFFFAOYSA-N 0.000 description 4
- SRCXETHSPBDKQD-UHFFFAOYSA-N 2-pentadecylthiomorpholine Chemical compound CCCCCCCCCCCCCCCC1CNCCS1 SRCXETHSPBDKQD-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- KOUAQOCYMAENKN-UHFFFAOYSA-N ethyl 2-bromohexanoate Chemical compound CCCCC(Br)C(=O)OCC KOUAQOCYMAENKN-UHFFFAOYSA-N 0.000 description 4
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- ANCSCGAGTWCCJY-UHFFFAOYSA-N 2-nonylthiomorpholine Chemical compound CCCCCCCCCC1CNCCS1 ANCSCGAGTWCCJY-UHFFFAOYSA-N 0.000 description 3
- PTOWQSPVNITXIN-UHFFFAOYSA-N 2-tridecylthiomorpholine Chemical compound CCCCCCCCCCCCCC1CNCCS1 PTOWQSPVNITXIN-UHFFFAOYSA-N 0.000 description 3
- SCPABRAAUUPLDH-UHFFFAOYSA-N 2-undecylthiomorpholine Chemical compound CCCCCCCCCCCC1CNCCS1 SCPABRAAUUPLDH-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000002467 anti-pepsin effect Effects 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
- 235000019341 magnesium sulphate Nutrition 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 3
- UOTMYNBWXDUBNX-UHFFFAOYSA-N 1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxyisoquinolin-2-ium;chloride Chemical group Cl.C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 UOTMYNBWXDUBNX-UHFFFAOYSA-N 0.000 description 2
- OGMADIBCHLQMIP-UHFFFAOYSA-N 2-aminoethanethiol;hydron;chloride Chemical compound Cl.NCCS OGMADIBCHLQMIP-UHFFFAOYSA-N 0.000 description 2
- IHAASKVYTDOONZ-UHFFFAOYSA-N 2-butylthiomorpholin-3-one Chemical compound CCCCC1SCCNC1=O IHAASKVYTDOONZ-UHFFFAOYSA-N 0.000 description 2
- RVRJFUUCVPPSGQ-UHFFFAOYSA-N 2-butylthiomorpholine Chemical compound CCCCC1CNCCS1 RVRJFUUCVPPSGQ-UHFFFAOYSA-N 0.000 description 2
- RAGSWDIQBBZLLL-UHFFFAOYSA-N 2-chloroethyl(diethyl)azanium;chloride Chemical compound Cl.CCN(CC)CCCl RAGSWDIQBBZLLL-UHFFFAOYSA-N 0.000 description 2
- QKFCTAFQXHWNMT-UHFFFAOYSA-N 2-decylthiomorpholin-3-one Chemical compound CCCCCCCCCCC1SCCNC1=O QKFCTAFQXHWNMT-UHFFFAOYSA-N 0.000 description 2
- WUMYMILYRWEMEX-UHFFFAOYSA-N 2-heptadecylthiomorpholine Chemical compound CCCCCCCCCCCCCCCCCC1CNCCS1 WUMYMILYRWEMEX-UHFFFAOYSA-N 0.000 description 2
- JWSAVCBWTLHZAL-UHFFFAOYSA-N 2-heptylthiomorpholin-3-one Chemical compound CCCCCCCC1SCCNC1=O JWSAVCBWTLHZAL-UHFFFAOYSA-N 0.000 description 2
- TYPBSYYDJRIIML-UHFFFAOYSA-N 2-heptylthiomorpholine Chemical compound CCCCCCCC1CNCCS1 TYPBSYYDJRIIML-UHFFFAOYSA-N 0.000 description 2
- OCEOJMQRLOGSQI-UHFFFAOYSA-N 2-octylthiomorpholin-3-one Chemical compound CCCCCCCCC1SCCNC1=O OCEOJMQRLOGSQI-UHFFFAOYSA-N 0.000 description 2
- JEKVCZXRNRIODG-UHFFFAOYSA-N 2-tridecylthiomorpholin-3-one Chemical compound CCCCCCCCCCCCCC1SCCNC1=O JEKVCZXRNRIODG-UHFFFAOYSA-N 0.000 description 2
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 208000008469 Peptic Ulcer Diseases 0.000 description 2
- 230000004520 agglutination Effects 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 229940097265 cysteamine hydrochloride Drugs 0.000 description 2
- 230000000762 glandular Effects 0.000 description 2
- KEMQGTRYUADPNZ-UHFFFAOYSA-N heptadecanoic acid Chemical compound CCCCCCCCCCCCCCCCC(O)=O KEMQGTRYUADPNZ-UHFFFAOYSA-N 0.000 description 2
- 229960000905 indomethacin Drugs 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- ISYWECDDZWTKFF-UHFFFAOYSA-N nonadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCCC(O)=O ISYWECDDZWTKFF-UHFFFAOYSA-N 0.000 description 2
- 229960003207 papaverine hydrochloride Drugs 0.000 description 2
- 208000011906 peptic ulcer disease Diseases 0.000 description 2
- 238000003359 percent control normalization Methods 0.000 description 2
- 210000004623 platelet-rich plasma Anatomy 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 2
- SZHOJFHSIKHZHA-UHFFFAOYSA-N tridecanoic acid Chemical compound CCCCCCCCCCCCC(O)=O SZHOJFHSIKHZHA-UHFFFAOYSA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- LQLJZSJKRYTKTP-UHFFFAOYSA-N 2-dimethylaminoethyl chloride hydrochloride Chemical compound Cl.CN(C)CCCl LQLJZSJKRYTKTP-UHFFFAOYSA-N 0.000 description 1
- WYOGMVFABMEFBV-UHFFFAOYSA-N 2-dodecylthiomorpholin-3-one Chemical compound CCCCCCCCCCCCC1SCCNC1=O WYOGMVFABMEFBV-UHFFFAOYSA-N 0.000 description 1
- DDKAGKSWPJCQPN-UHFFFAOYSA-N 2-hexylthiomorpholin-3-one Chemical compound CCCCCCC1SCCNC1=O DDKAGKSWPJCQPN-UHFFFAOYSA-N 0.000 description 1
- YKZVQXSMNYXNKA-UHFFFAOYSA-N 2-nonylthiomorpholin-3-one Chemical compound CCCCCCCCCC1SCCNC1=O YKZVQXSMNYXNKA-UHFFFAOYSA-N 0.000 description 1
- YCBNKFXWQMRMES-UHFFFAOYSA-N 2-pentadecylthiomorpholin-3-one Chemical compound CCCCCCCCCCCCCCCC1SCCNC1=O YCBNKFXWQMRMES-UHFFFAOYSA-N 0.000 description 1
- UZLTUBYPNJANAM-UHFFFAOYSA-N 2-tetradecylthiomorpholin-3-one Chemical compound CCCCCCCCCCCCCCC1SCCNC1=O UZLTUBYPNJANAM-UHFFFAOYSA-N 0.000 description 1
- CDMMGYLNHIJELR-UHFFFAOYSA-N 2-undecylthiomorpholin-3-one Chemical compound CCCCCCCCCCCC1SCCNC1=O CDMMGYLNHIJELR-UHFFFAOYSA-N 0.000 description 1
- TVKYKXAPUMUAML-UHFFFAOYSA-N 4-dodecylthiomorpholine Chemical compound CCCCCCCCCCCCN1CCSCC1 TVKYKXAPUMUAML-UHFFFAOYSA-N 0.000 description 1
- YEQQTKZGAYOSGG-UHFFFAOYSA-N 4-hexylthiomorpholine Chemical compound CCCCCCN1CCSCC1 YEQQTKZGAYOSGG-UHFFFAOYSA-N 0.000 description 1
- XGNAIIIIJBIFFI-UHFFFAOYSA-N 4-nonylthiomorpholine Chemical compound CCCCCCCCCN1CCSCC1 XGNAIIIIJBIFFI-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 206010042220 Stress ulcer Diseases 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000003218 coronary vasodilator agent Substances 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- NQGIJDNPUZEBRU-UHFFFAOYSA-N dodecanoyl chloride Chemical compound CCCCCCCCCCCC(Cl)=O NQGIJDNPUZEBRU-UHFFFAOYSA-N 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hcl hcl Chemical compound Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- YAQXGBBDJYBXKL-UHFFFAOYSA-N iron(2+);1,10-phenanthroline;dicyanide Chemical compound [Fe+2].N#[C-].N#[C-].C1=CN=C2C3=NC=CC=C3C=CC2=C1.C1=CN=C2C3=NC=CC=C3C=CC2=C1 YAQXGBBDJYBXKL-UHFFFAOYSA-N 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- IUSXYVRFJVAVOB-UHFFFAOYSA-N n-(2-chloroethyl)-n-propan-2-ylpropan-2-amine;hydron;chloride Chemical compound Cl.CC(C)N(C(C)C)CCCl IUSXYVRFJVAVOB-UHFFFAOYSA-N 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 229960002446 octanoic acid Drugs 0.000 description 1
- REEZZSHJLXOIHL-UHFFFAOYSA-N octanoyl chloride Chemical compound CCCCCCCC(Cl)=O REEZZSHJLXOIHL-UHFFFAOYSA-N 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- LPWCRLGKYWVLHQ-UHFFFAOYSA-N tetradecanoyl chloride Chemical compound CCCCCCCCCCCCCC(Cl)=O LPWCRLGKYWVLHQ-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000002834 transmittance Methods 0.000 description 1
- JUKPJGZUFHCZQI-UHFFFAOYSA-N undecanoyl chloride Chemical compound CCCCCCCCCCC(Cl)=O JUKPJGZUFHCZQI-UHFFFAOYSA-N 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 210000002417 xiphoid bone Anatomy 0.000 description 1
Landscapes
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
本発明は下記一般式〔〕で表わされる2−ア
ルキル−4−(2−アミノエチル)チオモルホリ
ン化合物およびその塩に関するものである。
式中R1は直鎖アルキル基を示し、その炭素数
は3〜17個である。R2は低級アルキル基を示す。
尚低級アルキル基とは炭素数1〜4個の直鎖ある
いは分枝のものをいう。塩としては塩酸塩等の無
機塩および酢酸塩、マレイン酸塩等の有機酸塩を
いう。
本発明化合物は、冠血管拡張,血小板凝集抑制
作用,抗不整脈作用,抗消化性潰瘍作用等を示
し、医薬品として期待される。
以下に本発明化合物の一般的製法を述べる。
一般式〔〕で表わされるα−ハロゲノ(好ま
しくはブロモ)脂肪酸エステル類を、システアミ
ン塩酸塩と反応させ、一般式〔〕で表わされる
化合物とし、〔〕を水素化リチウムアルミニウ
ム,ジボラン等の還元剤で還元して、一般式
〔〕で表わされる化合物を得る。さらに〔〕
を2−ジアルキルアミノエチルクロライド塩酸塩
と処理することより、本発明化合物を得た。
次に実施例によつて本発明化合物の製造例を示
す。
実施例 1
2−ブチル−4−(2−ジエチルアミノエチル)
チオモルホリンの製造
(イ) n−カプロン酸5.00g(0.043モル)にチオ
ニルクロライド7.67g(0.065モル)を加え、
30分間加熱還流する。過剰のチオニルクロライ
ドを減圧留去したのち、臭素7.43g(0.046モ
ル)を加え、80℃にて16時間撹拌する。反応溶
液を氷冷下エタノールで希釈し、減圧下エタノ
ールを留去する。α−ブロモカプロン酸エチル
エステルを黄色油状物質として9.20g(収率96
%)を得た。
IRνcm-1:2950,2920,2860,1720.
NMR(CDCl3)δ:0.80−2.30(9H,m),
1.39(3H,t,J=7.0Hz),3.75−4.40
(1H,m),3.96(2H,q,J=7.0Hz).
(ロ) 上記α−ブロモカプロン酸エチルエステル
5.000g(0.022モル),システアミン塩酸塩2.80
g(0.025モル),炭酸カリウム3.10g(0.022モ
ル)をエタノール20mlに加え、12時間加熱還流
する。エタノールを留去したのち、反応液を水
で希釈しクロロホルムで抽出。抽出液を水洗し
たのち硫酸マグネシウムで乾燥する。溶媒を留
去して2−ブチルチオモルホリン−3−オンを
無色油状物質として3.17g(収率82%)を得
た。
IRνcm-1:1650(−NHCO−)
NMR(CDCl3)δ:0.90(3H,t,J=6.0Hz),
1.10−2.00(6H,m),2.70−3.00(2H,m),
3.05−3.70(3H,m).
(ハ) 上記2−ブチルチオモルホリン−3−オン
3.17g(0.0183モル)水素化カリウムアルミニ
ウム1.39g(0.0366モル)を乾燥エタノール
100mlに加え2時間加熱還流する。反応液を氷
冷下、水で希釈し、エーテル層を分離する。こ
れを水洗したのち硫酸マグネシウムにて乾燥す
る。溶媒を留去して、2−ブチルチオモルホリ
ンを黄色油状物質として2.40g(収率83%)を
得た。
IRνcm-1:3260,2930,2860,1450.
NMR(CDCl3)δ:0.80−1.80(9H,m),
2.20−3.70(8H,m).
(ニ) 上記2−ブチルチオモルホリン2.00g
(0.0126モル),β−ジエチルアミノエチルクロ
ライド塩酸塩2.27g(0.0132モル),炭酸カリ
ウム1.74g(0.0126モル)をジメチルホルマミ
ド30mlに加え、90〜100℃にて12時間加熱撹拌
する。ジメチルホルマミドを減圧留去したの
ち、反応混合物を水で希釈し、エーテルで抽出
する。抽出液を水洗後、硫酸マグネシウムで乾
燥する。溶媒を留去して得た油状物質をシリカ
ゲルカラムにて分離精製して、標記化合物を無
色油状物質として1.83g(収率57%)を得た。
IRνcm-1:2960,2930,2800,1460.
NMR(CDCl3)δ:1.00(6H,t,J=6.0Hz),
0.80−1.80(9H,m),2.50(4H,q,
J=6.0Hz),2.10−3.20(11H,m).
これを2塩酸塩としてエタノール・エーテルか
ら再結晶して融点173−180℃の無色針状晶0.99g
(収率24%)を得た。
元素分析値C14H32Cl2N2S(分子量331.40とし
て)
計算値 C:50.74,H:9.73,N:8.45
実測値 C:50.60,H:9.50,N:8.18
実施例 2
4−(2−ジメチルアミノエチル)−2−ヘキシ
ルチオモルホリンの製造
(イ) 実施例1におけるn−カプロン酸の代わりに
2−カプリル酸25.00g(0.173モル)を使用し
た以外実施例(イ)と同様にして、エチルα−ブロ
モオクタネートを黄色油状物質として43.50g
(収率100%)を得た。
IRνcm-1:2920,,2950,1730,1240.
NMR(CDCl3)δ:0.90(3H,t,J=4.0Hz),
1.12−2.15(8H,m),1.29(3H,t,
J=7.0Hz),4.19(1H,t,J=6.0Hz),
2.24(2H,q,J=7.0Hz).
(ロ) 上記エチルα−ブロモオクテート38.60g
(0.154モル)を実施例1(ロ)と同様に処理して2
−ヘキシルチオモルホリン−3−オンを黄色油
状物質として28.18g(収率91%)を得た。
IRνcm-1:1650(−NHCO−)
NMR(CDCl3)δ:0.80−1.10(3H,t,
J=4.0Hz),1.10−1.60(10H,m),
2.70−3.00(2H,m),3.28−3.76(3H,
m),7.10(1H,b.s).
(ハ) 上記2−ヘキシルチオモルホリン−3−オン
28.00g(0.139モル)を実施例1(ハ)と同様に処
理して、2−ヘキシルチオモルホリンを無色油
状物質として21.59g(収率83%)を得た。
IRνcm-1:3250,2910,2850,1450.
NMR(CDCl3)δ:0.70−1.01(3H,t,J=
4.0Hz,1.05−1.70(10H,m),1.90
(1H,s),2.40−3.40(7H,m).
(ニ) 上記2−ヘキシルチオモルホリン2.00g
(0.0107モル)とβ−ジメチルアミノエチルク
ロライド塩酸塩2.31g(0.0160モル)を実施例
1(ニ)と同様に処理して標記化合物を油状物質と
して、2.20g(収率84%)を得た。
IRνcm-1:2920,2850,1450.
NMR(CDCl3)δ:0.70−1.20(13H,m),
2.26(6H,s),2.00−3.50(11H,m).
これを2塩酸塩としてエタノール・エーテルか
ら再結晶して融点98−100℃の無色針状晶0.80g
(収率31%)を得た。
元素分析値C14H32Cl2N2S(分子量317.40とし
て)
計算値 C:52.98,H:10.16,N:8.83
実測値 C:53.10,H:10.00,N:8.66
実施例 3
4−(2−ジエチルアミノエチル)−2−ヘキシ
ルチオモルホリンの製造
2−ヘキシルチオモルホリン2.00g(0.0106モ
ル),β−ジエチルアミノエチルクロライド塩酸
塩2.02g(0.0117モル)を用い、実施例1(ニ)と同
様に処理して標記化合物を黄色油状物質として
2.14g(収率70%)を得た。
IRνcm-1:2920,2850,2800,1450.
NMR(CDCl3)δ:0.70−1.50(13H,m),
1.06(6H,t,J=7.0Hz),2.10−3.25
(11H,m),2.60(4H,q,J=7.0Hz).
これを2塩酸塩としてエタノール・エーテルか
ら再結晶して融点197−201℃の無色針状晶として
1.40g(収率37%)を得た。
元素分析値C16H36Cl2N2S(分子量359.61とし
て)
計算値 C:53.44,H:10.09,N:7.79
実測値 C:53.13,H:9.99, N:7.50
実施例 4
4−(2−ジイソプロピルアミノエチル)−2−
ヘキシルチオモルホリンの製造
2−ヘキシルチオモルホリン2.00g(0.0106モ
ル),β−ジイソプロピルアミノエチルクロライ
ド塩酸塩2.350g(0.0117モル)を用い、実施例
1(ニ)と同様に処理して標記化合物を黄色油状物質
として2.88g(収率88%)を得た。
IRνcm-1:2950,2920,2850,2800,
1455.
NMR(CDCl3)δ:0.70−1.60(13H,m),
1.00(12H,d,J=6.0Hz),2.10−
3.30(13H,m).
これを2塩酸塩としてエタノール・エーテルか
ら再結晶して融点180−184℃の無色プリズム晶
2.15g(収率52%)を得た。
元素分析値C18H40Cl2N2S(分子量387.51とし
て)
計算値 C:55.79,H:10.40,N:7.23
実測値 C:55.50,H:9.98, N:7.00
実施例 5
4−(2−ジエチルアミノエチル)−2−ヘプチ
ルチオモルホリンの製造
(イ) ノナノイルクロライド25.00g(0.142モル)
に臭素27.16g(0.170モル)を加え80℃にて16
時間撹拌する。この反応混合物を氷冷下エタノ
ールで希釈し、減圧下エタノールを留去する。
エチルα−ブロモノナネートを黄色油状物質と
して37.52g(収率100%)を得た。
IRνcm-1:2930,2850,1735,1245.
NMR(CDCl3)δ:0.70−1.60(15H,m),
1.26(3H,J=7.0Hz),1.80−2.25
(2H,m),4.15(1H,t,J=6.0Hz),
4.21(2H,q,J=7.0Hz).
(ロ) 上記のエチルα−ブロモノナネート37.52g
(0.142モル)を用い、実施例1(ロ)と同様に処理
して2−ヘプチルチオモルホリン−3−オンを
無色油状物質として30.00g(収率98%)を得
た。
IRνcm-1:1645(−NHCO−)
NMR(CDCl3)δ:0.70−1.70(15H,m),
2.70−3.00(2H,m),3.25−3.80(3H,
m),7.50(1H,,b.s).
(ハ) 上記2−ヘプチルチオモルホリン−3−オン
25.00g(0.116モル)を用い実施例1(ハ)と同様
に処理して、2−ヘプチルチオモルホリンを無
色油状物質として18.60g(収率80%)を得た。
IRνcm-1:3250,2930,2860,1460.
NMR(CDCl3)δ:0.70−1.60(15H,m),
2.00(1H,s),2.40−3.70(7H,m).
(ニ) 上記2−ヘプチルチオモルホリン2.00g
(0.0099モル)を用い、実施例1(ニ)と同様に処
理して標記化合物を無色油状物質として1.70g
(収率57%)を得た。
IRνcm-1:2990,2950,2880,2820,
1480.
NMR(CDCl3)δ:0.70−1.60(15H,m),
1.00(6H,t,J=6.5Hz),2.10−3.20
(11H,m),2.52(4H,q,J=6.5Hz).
これを2塩酸塩としてエタノール:エーテルか
ら再結晶して、融点182−189℃の無色針状晶とし
て0.96g(収率26%)を得た。
元素分析値C17H38Cl2N2S(分子量373.48とし
て)
計算値 C:54.67,H:10.26,N:7.50
実測値 C:54.37,H:10.00,N:7.39
実施例 6
4−(2−ジメチルアミノエチル)−2−オクチ
ルチオモルホリンの製造
(イ) 実施例5(イ)におけるノナノイルクロライドの
代わりにカプリルクロライド25.00g(0.131モ
ル)を用い、同様に処理してエチルα−ブロモ
デカネートを黄色油状物質として35.00g(定
量的)を得た。
IRνcm-1:2920,2850,1730,1250,
1140.
NMR(CDCl3)δ:0.80−2.15(17H,m),
1.31(3H,t,J=7.0Hz),4.17(1H,t,
J=6.0Hz),4,24(2H,q,J=7.0Hz).
(ロ) 上記エチルα−ブロモデカネート35.00g
(0.131モル)を用い、実施例1(ロ)と同様に処理
して2−オクチルチオモルホリン−3−オンを
黄色油状物質として29.60g(収率98%)を得
た。
IRνcm-1:1660(−NHCO−)
NMR(CDCl3)δ:0.70−1.60(17H,m),
2.70−3.00(2H,m),3.28−3.80(3H,
m),7.10(1H,b.s).
(ハ) 上記2−オクチルチオモルホリン−3−オン
29.60g(0.129モル)を用い実施例1(ハ)と同様
に処理して2−オクチルチオモルホリンを無色
油状物質として19.52g(収率70%)を得た。
IRνcm-1:2920,2860,1460.
NMR(CDCl3)δ:0.70−1.60(17H,m),
2.00(1H,s),2.45−3.90(7H,m).
(ニ) 上記で得た2−オクチルチオモルホリン1.50
g(0.0069モル)を実施例1(ニ)と同様に処理し
て標記化合物を無色油状物質として1.56g(収
率78%)を得た。
IRνcm-1:2920,2850,1450.
NMR(CDCl3)δ:0.70−1.60(17H,m),
2.20(6H,s),2.46(4H,s),2.10−
3.20(7H,m).
これを2塩酸塩としてエタノール:エーテルか
ら再結晶して融点241−245℃の無色針状晶0.960
g(収率38%)を得た。
元素分析値C18H40Cl2N2S(分子量387.82とし
て)
計算値 C:53.46,H:10.10,N:7.79
実測値 C:53.40,H:9.98, N:7.49
実施例 7
4−(2−ジエチルアミノエチル)−2−オクチ
ルチオモルホリンの製造
実施例3における2−ヘキシルチオモルホリン
の代わりに2−オクチルチオモルホリン2.00g
(0.0093モル)を用い、同様に処理して標記化合
物を無色油状物質として1.87g(収率64%)を得
た。
IRνcm-1:2960,2930,2850,2800,
1460.
NMR(CDCl3)δ:0.70−1.00(3H,m),
1.02(6H,t,J=7.0Hz),1.26(14H,
b.s),2.00−3.7(11H,m),2.65
(4H,q,J=7.0Hz).
これを2塩酸塩としてエタノール・エーテルか
ら再結晶して融点167−170℃の無色針状晶として
1.22g(収率34%)を得た。
元素分析値C18H40Cl2N2S(分子量387.82とし
て)
計算値 C:55.75,H:9.88,N:7.22
実測値 C:55.60,H:9.60, N:7.00
実施例 8
4−(2−ジイソプロピルアミノエチル)−2−
オクチルチオモルホリンの製造
実施例4における2−ヘキシルチオモルホリン
の代りに2−オクチルチオモルホリン2.000g
(0.0093モル)を用い、以下実施例4と同様に処
理して標記化合物を無色油状物質として2.16g
(収率90%)を得た。
IRνcm-1:2950,2910,2850,2790,
1470.
NMR(CDCl3)δ:0.80−1.60(17H,m),
1.02(12H,d,J=6.0Hz),2.10−
3.30(13H,m).
これを2塩酸塩としてエタノール:エーテルか
ら再結晶して融点175−178℃の無色針状晶を0.68
g(収率16%)を得た。
元素分析値C20H44Cl2N2S(分子量415.56とし
て)
計算値 C:57.80,H:10.67,N:6.74
実測値 C:57.50,H:10.29, N:6.49
実施例 9
4−(2−ジエチルアミノエチル)−2−ノニル
チオモルホリンの製造
(イ) 実施例5(イ)におけるノナノイルクロライドの
代りにウンデカノイルクロライド9.41g
(0.0460モル)を用い、以下同様に処理してエ
チルα−ブロモデカネートを黄色油状物質とし
て13.47g(収率100%)を得た。
IRνcm-1:2920,2850,1730,1260,
1140.
NMR(CDCl3)δ:0.70−1.10(3H,m),
1.30(14H,b.s),1.31(3H,t,J=
7.0Hz),1.80−2.20(2H,m),4.18
(1H,t,J=6.0Hz),4.24(2H,q,
J=7.0Hz).
(ロ) 上記エチルα−ブロモデカネート13.47g
(0.0460モルを用い、実施例1(ロ)に従い、2−
ノニルチオモルホリン−3−オンを無色油状物
質として11.00g(収率98%)を得た。
IRνcm-1:1655(−NHCO−)
NMR(CDCl3)δ:0.70−1.10(3H,m),
1.30(16H,b.s),2.75−3.00(2H,
m),3.29−3.80(3H,m),7.15(1H,
b.s).
(ハ) 上記2−ノニルチオモルホリン−3−オン
4.00g(0.045モル)を実施例1(ハ)と同様に処
理して2−ノナニルチオモルホリンを無色油状
物質として7.04g(収率66%)を得た。
IRνcm-1:3250,2930,2855,1460.
NMR(CDCl3)δ:0.70−1.05(3H,m),
1.25(16H,m),2.30−3.65(8H,m).
(ニ) 上記2−ノナニルチオモルホリン2.00g
(0.0087モル)を用い、実施例3と同様に処理
して標記化合物を無色油状物質として2.14g
(収率57%)を得た。
IRνcm-1:2960,2930,2840,1460.
NMR(CDCl3)δ:0.70−1.05(3H,m),
1.00(6H,t,J=7.0Hz),1.25(16H,
b.s),2.10(−3.30(7H,m),2.50
(4H,s).
これを2塩酸塩とし、エタノール:エーテルか
ら再結晶して融点162−170℃の無色針状晶1.13g
(収率32%)を得た。
元素分析値C19H42Cl2N2S(分子量40.54として)
計算値 C:56.83,H:10.54,N:6.98
実測値 C:56.59,H:10.22,N:6.59
実施例 10
4−(2−ジイソプロピルアミノエチル)−2−
ノニルチオモルホリンの製造
実施例4における2−ヘキシルチオモルホリン
の代りに2−ノニルチオモルホリン2.00g
(0.0087モル)を用い、同様に処理して標記化合
物を無色油状物質として2.56g(収率83%)を得
た。
IRνcm-1:2950,2920,2850,2800,
1665,1455.
NMR(CDCl3)δ:0.70−1.60(19H,m),
1.02(12H,d,J=6.0Hz),2.10−
3.25(11H,m).
これを2塩酸塩とし、エタノール:エーテルか
ら再結晶して融点154−165℃の無色針状晶として
1.64g(収率44%)を得た。
元素分析値C21H46Cl2N2S(分子量429.59とし
て)
計算値 C:58.71,H:10.79,N:6.52
実測値 C:58.60,H:10.66, N:6.40
実施例 11
2−デシル−(2−ジメチルアミノエチル)チ
オモルホリンの製造
(イ) 実施例5(イ)におけるノナノイルクロライドの
代りにドデカノイルクロライド22.00g
(0.1006モル)を用い、以下同様に処理してエ
チルα−ブロモデカネートを黄色油状物質とし
て30.70g(定量的)を得た。
IRνcm-1:2930,2850,1735,1255,
1145.
NMR(CDCl3)δ:0.70−1.60(19H,m),
1.31(3H,t,J=7.0Hz),1.85−2.40
(2H,m),4.17(1H,t,J=6.0Hz),
4.24(2H,q,J=7.0Hz).
(ロ) 上記エチルα−ブロモドデカネート30.70g
(0.1006モル)を用い実施例1(ロ)と同様に処理
して、2−デシルチオモルホリン−3−オンを
エーテル:ヘキサンから再結晶して融点56−57
℃の無色プリズム晶として24.40g(収率94%)
を得た。
IRνcm-1:1660(−NHCO−)
NMR(CDCl3)δ:0.70−1.70(21H,m),
2.70−3.00(2H,m),3.25−3.75(3H,
m),6.80(1H,b.s).
(ハ) 上記2−デシルチオモルホリン−3−オン
20.00g(0.0777モル)を実施例1(ハ)と同様に
処理して、2−デシルチオモルホリンを無色油
状物質として14.76g(収率78%)を得た。
IRνcm-1:3250,2920,2850,1455.
NMR(CDCl3)δ:0.70−1.80(22H,m),
2.40−3.35(76H,m).
(ニ) 上記2−デシルチオモルホリン2.00g
(0.0082モル)を用い、実施例1(ニ)と同様に処
理して標記化合物を無色油状物質として1.26g
(収率49%)を得た。
IRνcm-1:2920,2850,1450.
NMR(CDCl3)δ:0.70−1.60(21H,m),
2.27(6H,s),2.15−3.30(11H,m).
これを2塩酸塩とし、エタノール:エーテルか
ら再結晶して融点134−135℃の無色プリズム晶
1.05g(収率33%)を得た。
元素分析値C18H40Cl2N2S(分子量387.51とし
て)
計算値 C:55.79,H:10.40,N:7.23
実測値 C:55.66,H:10.20,N:7.00
実施例 12
2−デシル−4−(2−ジエチルアミノエチル)
チオモルホリンの製造
実施例3における2−ヘキシルチオモルホリン
の代りに2−デシルチオモルホリン2.00g
(0.0082モル)を用い、同様に処理して標記化合
物を無色油状物質として2.450(収率86%)を得
た。
IRνcm-1:2960,2920,2850,2800,
1460.
NMR(CDCl3)δ:0.70−1.55(21H,m),
1.03(6H,t,J=7.0Hz),2.10−3.20
(11H,m),2.55(4H,q,J=7.0Hz).
これを2塩酸塩としエタノール:エーテルから
再結晶して融点193−197℃の無色プリズム晶を
0.600g(収率18%)を得た。
元素分析値C20H44Cl2N2S(分子量415.56とし
て)
計算値 C:57.81,H:10.67,N:6.74
実測値 C:57.80,H:10.62,N:7.01
実施例 13
2−デシル−4−(2−ジイソプロピルアミノ
エチル)チオモルホリンの製造
実施例4における2−ヘキシルチオモルホリン
の代りに2−デシルチオモルホリン2.00g
(0.0082モル)を用い、以下同様に処理して、標
記化合物を無色油状物質として2.90g(収率95
%)を得た。
IRνcm-1:2960,2930,2850,2800,
1460.
NMR(CDCl3)δ:0.70−1.60(21H,m),
1.01(12H,d,J=6.0Hz),2.10−
3.25(13H,m).
これを2塩酸塩とし、エタノール:エーテルか
ら再結晶して融点176−178℃の無色プリズム晶と
して2.33g(収率68%)を得た。
元素分析値C22H48Cl2N2S(分子量443.62とし
て)
計算値 C:59.57,H:10.91,N:6.31
実測値 C:58.99,H:10.59,N:6.01
実施例 14
4−(2−ジエチルアミノエチル)−2−ウンデ
シルチオモルホリンの製造
(イ) 実施例1(イ)におけるn−カプロン酸の代りに
トリデカン酸20.00g(0.0933モル)を用い、
以下同様に処理してエチルα−ブロモトリデカ
ネートを黄色油状物質として29.97g(収率100
%)を得た。
IRνcm-1:2930,2850,1730,1260,
1155.
NMR(CDCl3)δ:0.70−1.05(3H,m),
1.29(18H,b.s),1.30(3H,t,J=
7.0Hz),1.80−2.30(2H,m),4.17
(1H,t,J=6.0Hz),4.22(2H,q,J=
7.0Hz).
(ロ) 上記エチルα−ブロモトリデカネート29.97
g(0.0933モル)を用い、実施例1(ロ)と同様に
処理して2−ウンデシルチオモルホリン−3−
オンを無色油状物質として24.66g(収率97%)
を得た。
IRνcm-1:1660(−NHCO−)
NMR(CDCl3)δ:0.70−1.10(3H,m),
1.28(20H,b.s),2.70−3.00(2H,
m),3.28−3.71(3H,m),7.15(1H,
b.s).
(ハ) 上記2−ウンデシルチオモルホリン−3−オ
ン20.00g(0.0734モル)を実施例1(ハ)と同様
に処理して、2−ウンデシルチオモルホリンを
無色油状物質として17.21g(収率91%)を得
た。
IRνcm-1:2250,2920,2850,1460.
NMR(CDCl3)δ:0.70−1.10(3H,m),
1.27(20H,b.s)1.85(1H,b.s),
2.30−3.45(7H,m).
(ニ) 上記2−ウンデシルチオモルホリン2.00g
(0.0077モル)を用い、実施例3と同様に処理
して標記化合物を無色油状物質として1.73g
(収率63%)を得た。
IRνcm-1:2960,2930,2850,2800,
1460.
NMR(CDCl3)δ:0.75−1.10(3H,m),
1.06(6H,t,J=7.0Hz),1.25(20H,
b.s),2.10−3.20(15H,m).
これを2塩酸塩としてエタノール:エーテルか
ら再結晶して融点175−183℃の無色プリズム晶と
して0.650g(収率70%)を得た。
元素分析値C21H46Cl2N2S(分子量429.59とし
て)
計算値 C:58.72,H:10.79,N:6.52
実測値 C:58.55,H:10.68,N:6.50
実施例 15
4−(2−ジイソプロピルアミノエチル)−2−
ウンデシルチオモルホリンの製造
実施例4における2−ヘキシルチオモルホリン
の代りに2−ウンデシルチオモルホリン2.00g
(0.0077モル)を用い、同様に処理し標記化合物
を無色油状物質として2.54g(収率86%)を得
た。
IRνcm-1:2960,2920,2850,2800,
1460.
NMR(CDCl3)δ:0.70−1.60(23H,m),
1.00(12H,d,J=6.0Hz),2.00−2.30
(13H,m).
これを2塩酸塩としてエタノール:エーテルか
ら再結晶して融点162−168℃の無色プリズム晶を
1.21g(収率34%)を得た。
元素分析値C23H50Cl2N2S(分子量457.65とし
て)
計算値 C:60.36,H:11.01,N:6.12
実測値 C:60.12,H:10.98,N:5.98
実施例 16
4−(2−ジメチルアミノエチル)−2−ドデシ
ルチオモルホリンの製造
(イ) 実施例5(イ)におけるノナノイルクロライドの
代りにテトラデカノイルクロライド26.00g
(0.1053モル)を用い、同様に処理してエチル
α−ブロモテトラデカネートを黄色油状物質と
して35.30g(定量的)を得た。
IRνcm-1:2920,2850,1735,1255,
1160.
NMR(CDCl3)δ:0.70−1.60(23H,m),
1.31(3H,t,J=7.0Hz),1.80−2.40
(2H,m),4.20(1H(1H,t,J=6.0Hz),
4.25(2H,q,J=7.0Hz).
(ロ) 上記エチルα−ブロモデカネート35.30g
(0.1053モルを用い、実施例1(ロ)と同様に処理
して2−ドデシルチオモルホリン−3−オンを
得、これをエーテル:ヘキサンから再結晶して
融点68−69℃の無色プリズム晶として30.30g
(収率100%)を得た。
IRνcm-1:1655(−NHCO−)
NMR(CDCl3)δ:0.70−1.00(3H,m),
1.26(22H,b.s),2.70−3.00(2H,m),
3.20−3.80(3H,m),6.55(1H,b.s).
(ハ) 上記2−ドデシルチオモルホリン20.00g
(0.070モル)を用い、実施例1(ハ)と同様に処理
して2−ドデシルチオモルホリンを無色油状物
質として16.80g(収率88%)を得た。
IRνcm-1:3200,2910,2840,1460.
NMR(CDCl3)δ:0.70−1.00(3H,m),
1.25(22H,b.s),2.20(1H,s)
2.45−3.75(7H,m).
(ニ) 上記で得た2−ドデシルチオモルホリン2.00
g(0.0074モル)を用い、実施例2(ニ)と同様に
処理して標記化合物を無色油状物質として1.32
g(収率74%)を得た。
IRνcm-1:2930,2850,1455.
NMR(CDCl3)δ:0.70−1.60(25H,m),
2.23(6H,s),2.01−3.25(11H,m).
これを2塩酸塩としてエタノール:エーテルか
ら再結晶して融点137−140℃の無色針状晶1.00g
(収率33%)を得た。
元素分析値C20H44Cl2N2S(分子量415.56とし
て)
計算値 C:57.81,H:10.67,N:6.74
実測値 C:57.60,H:10.42,N:6.50
実施例 17
4−(2−ジエチルアミノエチル)−2−ドデシ
ルチオモルホリンの製造
実施例3における2−ヘキシルチオモルホリン
の代りに2−ドデシルチオモルホリン2.00g
(0.0074モル)を用い、同様に処理して標記化合
物を無色油状物質として2.20g(収率77%)を得
た。
IRνcm-1:2960,2930,2850,2800,
1465.
NMR(CDCl3)δ:0.70−1.60(25H,m),
1.06(6H,t,J=7.0Hz),2.10−3.20
(15H,m).
これを2塩酸塩とし、エタノール:エーテルか
ら再結晶して融点156−161℃の無色針状晶として
1.120g(収率33%)を得た。
元素分析値C22H48Cl2N2S(分子量443.62とし
て)
計算値 C:59.57,H:10.91,N:6.31
実測値 C:59.30,H:10.80,N:6.00
実施例 18
4−(2−ジイソプロピルアミノエチル)−2−
ドデシルチオモルホリンの製造
実施例4における2−ヘキシルチオモルホリン
の代りに2−ドデシルチオモルホリン2.00g
(0.0074モル)を用い、同様に処理して標記化合
物を無色油状物質として2.12g(収率72%)を得
た。
IRνcm-1:2960,2930,2850,2800,
1460.
NMR(CDCl3)δ:0.70−1.65(25H,m),
1.00(12H,t,J=6.0Hz),2.10−
3.40(15H,m).
これを2塩酸塩としてエタノール・エーテルか
ら再結晶して融点168−171℃の無色プリズム晶を
1.45g(収率49%)を得た。
元素分析値C24H52Cl2N2S(分子量471.67とし
て)
計算値 C:61.12,H:11.11,N:5.94
実測値 C:61.00,H:10.98,N:5.66
実施例 19
4−(2−ジメチルアミノエチル)−2−トリデ
シルチオモルホリンの製造
(イ) 実施例1(イ)におけるn−カプロン酸の代りに
ペンタデカン酸20.00g(0.0825モル)を用い、
同様に処理してエチルα−ブロモペンタデカネ
ートを黄色油状物質として27.80g(定量的)
を得た。
IRνcm-1:2920,2860,1740,1260,
1165.
NMR(CDCl3)δ:0.70−1.05(3H,m),
1.30(3H,t,J=7.0Hz),1.26(20H,
b.s),1.85−2.20(2H,m),4.19
(1H,t,J=6.0Hz),4.25(2H,q,
J=7.0Hz).
(ロ) 上記で得たエチルα−ブロモペンタデカネー
ト27.80g(0.0825モル)を用い、実施例1(ロ)
と同様に処理して2−トリデシルチオモルホリ
ン−3−オンを得、これをエーテル:ヘキサン
から再結晶して融点65−66℃の無色プリズム晶
を20.49g(収率87%)を得た。
IRνcm-1:1650(−NHCO−)
NMR(CDCl3)δ:0.70−1.05(3H,m),
1.25(24H,b.s),2.69−2.95(2H,
m),3.20−3.70(3H,m),6.65(1H,
b.s).
(ハ) 上記の2−トリデシルチオモルホリン−3−
オン23.50g(0.0825モル)を用い、実施例1
(ハ)と同様に処理して2−トリデシルチオモルホ
リンを無色油状物質として17.68g(収率75%)
を得た。
IRνcm-1:3250,2930,2850,1450.
NMR(CDCl3)δ:0.70−1.80(27H,m),
2.40−3.35(7H,m).
(ニ) 上記の2−トリデシルチオモルホリン2.00g
(0.0070モル)を用い、実施例2(ニ)と同様に処
理して標記化合物を無色油状物質として1.75g
(収率72%)を得た。
IRνcm-1:2920,2850,1450.
NMR(CDCl3)δ:0.70−1.60(27H,m),
2.26(6H,s),2.15−3.32(11H,m).
これを2塩酸塩としてエタノール:エーテルか
ら再結晶して融点88−92℃の無色針状晶0.960g
(収率32%)を得た。
(吸温性にて元素分析せず)
実施例 20
4−(2−ジエチルアミノエチル)−2−トリデ
シルチオモルホリンの製造
実施例3における2−ヘキシルチオモルホリン
の代りに2−ドデシルチオモルホリン2.00g
(0.0070モル)を用い、同様に処理して標記化合
物を無色油状物質として1.56g(収率59%)を得
た。
IRνcm-1:2970,2940,2860,2820,
1465.
NMR(CDCl3)δ:0.70−1.05(3H,m),
1.02(6H,t,J=7.0Hz),1.26(24H,
b.s),2.10−3.2(11H,m),2.58
(4H,q,J=7.0Hz).
これを2塩酸塩として、エタノール:エーテル
から再結晶して融点176−183℃の無色針状晶とし
て0.860g(収率27%)を得た。
元素分析値C23H50Cl2N2S(分子量475.65とし
て)
計算値 C:60.36,H:11.01,N:6.12
実測値 C:60.11,H:10.92, N:5.98
実施例 21
4−(2−ジイソプロピルアミノエチル)−2−
トリデシルチオモルホリンの製造
実施例4における2−ヘキシルチオモルホリン
の代りに2−トリデシルチオモルホリン2.00g
(0.0070モル)を用い、同様に処理して標記化合
物を無色油状物質として2.32g(収率80%)を得
た。
IRνcm-1:2960,2930,2850,2800,1460.
NMR(CDCl3)δ:0.70−1.10(3H,m),
1.03(12H,d,J=6.0Hz),1.28
(24H,b.s),2.10−3.25(13H,m).
これを2塩酸塩とし、エタノール:エーテルか
ら再結晶して融点168−171℃の無色プリズム晶と
して1.50g(収率44%)を得た。
元素分析値C25H54Cl2N2S(分子量485.70とし
て)計算値 C:61.82,H:11.21,N:5.77
実測値 C:61.66,H:11.01,N:5.42
実施例 22
4−(2−ジエチルアミノエチル)−2−テトラ
デシルチオモルホリンの製造
(イ) 実施例5(イ)におけるノナノイルクロライドの
代りにパルミトイルクロライド25.00g(0.09
モル)を用い、同様に処理してエチルα−ブロ
モヘキサデカネートを黄色油状物質として
33.80g(定量的)を得た。
IRνcm-1:2920,2850,1730,1255,
1140.
NMR(CDCl3)δ:0.70−1.05(3H,m),
1.28(26H,b.s)1.30(1H,t,J=
7.0Hz),1.80−2.30(2H,m),4.13
(1H,t,J=6.0Hz),4.21(2H,q,J=
7.0Hz).
(ロ) 上記エチルα−ブロモヘキサデカネート
33.80g(0.091モル)を用い、実施例1(ロ)と同
様に処理して2−テトラデシルチオモルホリン
−3−オンを無色油状物質として26.80g(収
率94%)を得た。
IRνcm-1:1660(−NHCO−)
NMR(CDCl3)δ:0.70−1.10(3H,m),
1.30(26H,b.s),2.71−3.00(2H,
m),3.10−3.75(3H,m),7.10(1H,
b.s).
(ハ) 上記2−テトラデシルチオモルホリン−3−
オンを用い、実施例1(ハ)と同様に処理して2−
テトラデシルチオモルホリンを無色油状物質と
して16.25g(収率85%)を得た。
IRνcm-1:2960,2930,2860,2820,
1465.
NMR(CDCl3)δ:0.70−1.00(3H,m),
1.25(26H,b.s),1.85(1H,s),
2.20−3.70(7H,m).
(ニ) 上記テトラデシルチオモルホリン2.00g
(0.0067モル)を用い、実施例1(ニ)と同様に処
理して標記化合物を無色油状物質として1.56g
(収率59%)を得た。
IRνcm-1:2960,2900,2850,2800,
1460.
NMR(CDCl3)δ:0.70−1.00(3H,m),
1.05(6H,t,J=7.0Hz),1.25(26H,
b.s),2.01−3.20(11H,m),2.57
(4H,q,J=7.0Hz).
これを2塩酸塩としてエタノール:アセトンか
ら再結晶して融点158−165℃の無色プリズム晶と
して0.550g(収率17%)を得た。
元素分析値C24H52Cl2N2S(分子量471.67とし
て)
計算値 C:61.12,H:11.11,N:5.94
実測値 C:60.90,H:10.79,N:5.80
実施例 23
4−(2−ジエチルアミノエチル)−2−ペンタ
デシルチオモルホリンの製造
(イ) 実施例1(イ)におけるn−カプロン酸の代りに
ヘプタデカン酸20.00g(0.074モル)を用い、
同様に処理してエチルα−ブロモヘプタデカネ
ートを黄色油状物質として27.00g(定量的)
を得た。
IRνcm-1:2920,2850,1735,1250,
1140.
NMR(CDCl3)δ:0.70−1.05(3H,m),
1.25(26H,b.s),1.30(3H,t,J=
7.0Hz),1.80−2.15(1H,m),4.15
(1H,t,J=6.0Hz),4.22(2H,q,
J=7.0Hz).
(ロ) 上記のエチルα−ブロモヘプタデカネート
27.00g(0.0740モル)を用い、実施例1(ロ)と
同様に処理して2−ペンタデシルチオモルホリ
ン−3−オンを得、エーテル:ヘキサンから再
結晶して融点68−69℃の無色プリズム晶として
22.00g(収率96%)を得た。
IRνcm-1:1655(−NHCO−)
NMR(CDCl3)δ:0.70−1.05(3H,m),
1.26(28H,b.s),2.60−3.00(2H,
m),3.20−3.70(3H,m),6.50(1H,
b.s).
(ハ) 上記2−ペンタデシルチオモルホリン−3−
オン20.000g(0.0642モル)を用い実施例1(ハ)
と同様に処理して2−ペンタデシルチオモルホ
リンを無色油状物質として14.40g(収率72%)
を得た。
IRνcm-1:2960,2920,2850,2800,
1460.
NMR(CDCl3)δ:0.70−1.00(3H,m),
1.25(26H,m),1.85(1H,s),
2.20−3.70(7H,m).
(ニ) 上記の2−ペンタデシルチオモルホリン2.00
g(0.0064モル)を実施例2(ニ)と同様に処理し
て標記化合物を無色油状物質として2.03g(収
率77%)を得た。
IRνcm-1:2960,2900,2840,2800,
1450.
NMR(CDCl3)δ:0.70−1.05(3H,m),
1.06(6H,t,J=7.0Hz),1.25(28H,
b.s),2.01−3.20(11H,m),2.56
(4H,q,J=7.0Hz).
これを2塩酸塩としてエタノール:エーテルか
ら再結晶して融点180−186℃の無色プリズム晶を
1.00g(収率32%)を得た。
(吸温性のため元素分析せず)
実施例 24
4−(2−ジエチルアミノエチル)−2−ペンタ
デシルチオモルホリンの製造
実施例3における2−ヘキシルチオモルホリン
の代りに2−ペンタデシルチオモルホリン2.00g
(0.0064モル)を用い、同様に処理して標記化合
物を無色油状物質として2.03g(収率77%)を得
た。
IRνcm-1:2960,2930,2850,2800,
1460.
NMR(CDCl3)δ:0.70−1.05(3H,m),
1.01(6H,t,J=7.0Hz),1.25(28H,
b.s),2.20−3.20(11H,m),2.50
(4H,q,J=7.0Hz).
これを2塩酸塩としてエタノール:エーテルか
ら再結晶して融点180−186℃の無色プリズム晶と
して1.00g(収率32%)を得た。
元素分析値C25H54Cl2N2S(分子量485.70とし
て)
計算値 C:61.82,H:11.21,N:5.77
実測値 C:61.50,H:10.98, N:5.60
実施例 25
4−(2−ジイソプロピルアミノエチル)−2−
ペンタデシルチオモルホリンの製造
実施例4における2−ヘキシルチオモルホリン
の代りに2−ペンタデシルチオモルホリン2.00g
(0.0064モル)を用い、同様に処理して標記化合
物を無色油状物質として2.13g(収率76%)を得
た。
IRνcm-1:3020,2955,1460.
NMR(CDCl3)δ:0.98(12H,d,J=6.0Hz)
0.70−1.50(31H,m),2.00−3.20
(11H,m).
これを2塩酸塩としてエタノール:エーテルか
ら再結晶して融点168−171℃の無色プリズム晶を
1.98g(収率71%)を得た。
元素分析値C27H56Cl2N2S(分子量511.74とし
て)
計算値 C:63.37,H:11.03,N:5.47
実測値 C:63.05,H:10.98,N:5.20
実施例 26
4−(2−ジエチルアミノエチル)−2−ヘプタ
デシルチオモルホリンの製造
(イ) 実施例1(イ)におけるn−カプロン酸の代りに
ノナデカン酸5.00g(0.0167モル)を用い、同
様に処理してエチルα−ブロモノナデカネート
を黄色油状物質として6.59g(定量的)を得
た。
IRνcm-1:2930,2860,1740,1260,
1150.
NMR(CDCl3)δ:0.70−1.10(3H,m),
1.28(28H,b.s),1.80−2.25(2H,
m),4.16(1H,t,J=6.0Hz),4.23
(2H,q,J=7.0Hz).
(ロ) 上記のエチルα−ブロモノナデカネート5.00
g(0.0127モル)を用い、実施例1(ロ)と同様に
処理して2−ヘプタデシルチオモルホリン−3
−オンを得、これをクロロホルム:n−ヘキサ
ンから再結晶して融点83℃の無色針状晶3.55g
(収率82%)を得た。
IRνcm-1:1650(−NHCO−)
NMR(CDCl3)δ:0.70−1.10(3H,m),
1.28(32H,b.s),2.65−3.05(2H,
m),3.20−3.70(3H,m),7.00(1H,
m).
(ハ) 上記の2−ヘプタデシルチオモルホリン−3
−オン2.60g(0.0073モル)を用い、実施例1
(ハ)と同様に処理して2−ヘプタデシルチオモル
ホリンを無色油状物質として2.50g(収率100
%)を得た。
IRνcm-1:3250,2930,2550,1460.
NMR(CDCl3)δ:0.70−1.00(3H,m),
1.26(32H,b.s)1.70(1H,s),
2.20−3.60(7H,m).
(ニ) 上記2−ヘプタデシルチオモルホリン2.000
g(0.0058モル)を用い、実施例3と同様に処
理して標記化合物を無色油状物質として1.85g
(収率72%)を得た。
IRνcm-1:2960,2930,2850,2800
1460.
NMR(CDCl3)δ:0.65−1.00(3H,m),
1.04(6H,t,J=7.0Hz),1.28(32H,
b.s),2.20−3.20(15H,m).
これを2塩酸塩としてエタノール:エーテルか
ら再結晶して融点194−197℃の無色針状晶として
1.05g(収率36%)を得た。
元素分析値C27H58Cl2N2S(分子量513.76とし
て)
計算値 C:63.12,H:10.99,N:5.45
実測値 C:62.99,H:10.69,N:5.18
本発明化合物およびその生理的に許容される塩
類は、優れた冠血管拡張作用,血小板凝集能阻害
作用並びに抗消化性潰瘍作用等を有し、医薬とし
て有用である。本発明の代表的化合物の薬理作用
について、以下に説明する。
1 血小板凝集抑制作用
ウサギの耳動脈よりクエン酸ナトリウムを抗凝
固剤として用いて採血する。遠心分画によつて多
血小板血漿(PRP)と乏血小板血漿(PPP)を
得る。血小板数を40万/mm2に調整したPRP250μ
をアグレゴメーター(理化電機製HUM式)の
キユベツトに入れ、37℃でインキユベートしなが
ら1ミリモルの塩化カルシウムを加える。1分後
に被検化合物を適量加える。更に1分後に凝集剤
としてアデノシン二リン酸(ADP)10μモルまた
はコラーゲン38μg/mlまたはアラキドン酸0.3ミ
リモルを加え、光の透過率の変化をアグレゴメー
ターで測定する。凝集作用は対照の最大凝集を
100としてその抑制率を求め凝集を80%抑制する
試料濃度(IC50μg/ml)で比較した。その結果
を次表に示す。
The present invention relates to a 2-alkyl-4-(2-aminoethyl)thiomorpholine compound represented by the following general formula [] and a salt thereof. In the formula, R 1 represents a straight chain alkyl group, and has 3 to 17 carbon atoms. R 2 represents a lower alkyl group.
Note that the lower alkyl group refers to a straight chain or branched group having 1 to 4 carbon atoms. Salts include inorganic salts such as hydrochloride and organic acid salts such as acetate and maleate. The compound of the present invention exhibits coronary vasodilation, platelet aggregation inhibiting action, antiarrhythmia action, antipeptic ulcer action, etc., and is expected to be used as a pharmaceutical. A general method for producing the compound of the present invention will be described below. An α-halogeno (preferably bromo) fatty acid ester represented by the general formula [] is reacted with cysteamine hydrochloride to form a compound represented by the general formula [], and [] is a reducing agent such as lithium aluminum hydride or diborane. A compound represented by the general formula [] is obtained. moreover〔〕
The compound of the present invention was obtained by treating with 2-dialkylaminoethyl chloride hydrochloride. Next, examples of manufacturing the compounds of the present invention will be shown in Examples. Example 1 2-butyl-4-(2-diethylaminoethyl)
Production of thiomorpholine (a) Add 7.67 g (0.065 mol) of thionyl chloride to 5.00 g (0.043 mol) of n-caproic acid,
Heat to reflux for 30 minutes. After removing excess thionyl chloride under reduced pressure, 7.43 g (0.046 mol) of bromine was added, and the mixture was stirred at 80°C for 16 hours. The reaction solution was diluted with ethanol under ice-cooling, and the ethanol was distilled off under reduced pressure. 9.20 g of α-bromocaproic acid ethyl ester as a yellow oil (yield: 96
%) was obtained. IRνcm -1 : 2950, 2920, 2860, 1720. NMR (CDCl 3 ) δ: 0.80-2.30 (9H, m), 1.39 (3H, t, J = 7.0Hz), 3.75-4.40 (1H, m), 3.96 (2H, q, J = 7.0Hz). (b) The above α-bromocaproic acid ethyl ester
5.000g (0.022mol), cysteamine hydrochloride 2.80
(0.025 mol) and 3.10 g (0.022 mol) of potassium carbonate were added to 20 ml of ethanol and heated under reflux for 12 hours. After distilling off the ethanol, the reaction solution was diluted with water and extracted with chloroform. The extract is washed with water and then dried with magnesium sulfate. The solvent was distilled off to obtain 3.17 g (82% yield) of 2-butylthiomorpholin-3-one as a colorless oil. IRνcm -1 : 1650 (-NHCO-) NMR (CDCl 3 ) δ: 0.90 (3H, t, J = 6.0Hz), 1.10-2.00 (6H, m), 2.70-3.00 (2H, m), 3.05-3.70 (3H, m). (c) The above 2-butylthiomorpholin-3-one
3.17g (0.0183mol) potassium aluminum hydride 1.39g (0.0366mol) in dry ethanol
Add to 100ml and heat under reflux for 2 hours. The reaction solution was diluted with water under ice cooling, and the ether layer was separated. After washing this with water, it is dried with magnesium sulfate. The solvent was distilled off to obtain 2.40 g (83% yield) of 2-butylthiomorpholine as a yellow oil. IRνcm -1 : 3260, 2930, 2860, 1450. NMR (CDCl 3 ) δ: 0.80-1.80 (9H, m), 2.20-3.70 (8H, m). (d) 2.00g of the above 2-butylthiomorpholine
(0.0126 mol), 2.27 g (0.0132 mol) of β-diethylaminoethyl chloride hydrochloride, and 1.74 g (0.0126 mol) of potassium carbonate were added to 30 ml of dimethylformamide, and the mixture was heated and stirred at 90 to 100°C for 12 hours. After removing dimethylformamide under reduced pressure, the reaction mixture is diluted with water and extracted with ether. After washing the extract with water, it is dried with magnesium sulfate. The oily substance obtained by distilling off the solvent was separated and purified using a silica gel column to obtain 1.83g (yield 57%) of the title compound as a colorless oily substance. IRνcm -1 : 2960, 2930, 2800, 1460. NMR (CDCl 3 ) δ: 1.00 (6H, t, J = 6.0Hz), 0.80−1.80 (9H, m), 2.50 (4H, q, J = 6.0Hz) ), 2.10−3.20 (11H, m). This was recrystallized as dihydrochloride from ethanol/ether to give 0.99 g of colorless needles with a melting point of 173-180℃.
(yield 24%). Elemental analysis value C 14 H 32 Cl 2 N 2 S (assuming molecular weight 331.40) Calculated value C: 50.74, H: 9.73, N: 8.45 Actual value C: 50.60, H: 9.50, N: 8.18 Example 2 4-(2 -dimethylaminoethyl)-2-hexylthiomorpholine (a) Same as Example (a) except that 25.00 g (0.173 mol) of 2-caprylic acid was used instead of n-caproic acid in Example 1. , 43.50 g of ethyl α-bromooctanate as a yellow oil
(yield 100%). IRνcm -1 : 2920, 2950, 1730, 1240. NMR (CDCl 3 ) δ: 0.90 (3H, t, J = 4.0Hz), 1.12-2.15 (8H, m), 1.29 (3H, t, J = 7.0 Hz), 4.19 (1H, t, J = 6.0Hz), 2.24 (2H, q, J = 7.0Hz). (b) 38.60g of the above ethyl α-bromooctate
(0.154 mol) was treated in the same manner as in Example 1 (b) to obtain 2
28.18 g (yield 91%) of -hexylthiomorpholin-3-one was obtained as a yellow oil. IRνcm -1 : 1650 (-NHCO-) NMR (CDCl 3 ) δ: 0.80-1.10 (3H, t, J = 4.0Hz), 1.10-1.60 (10H, m), 2.70-3.00 (2H, m), 3.28 −3.76 (3H, m), 7.10 (1H, bs). (c) The above 2-hexylthiomorpholin-3-one
28.00 g (0.139 mol) was treated in the same manner as in Example 1 (c) to obtain 21.59 g (83% yield) of 2-hexylthiomorpholine as a colorless oil. IRνcm -1 : 3250, 2910, 2850, 1450. NMR (CDCl 3 ) δ: 0.70−1.01 (3H, t, J = 4.0Hz, 1.05−1.70 (10H, m), 1.90 (1H, s), 2.40− 3.40 (7H, m). (d) 2.00g of the above 2-hexylthiomorpholine
(0.0107 mol) and 2.31 g (0.0160 mol) of β-dimethylaminoethyl chloride hydrochloride were treated in the same manner as in Example 1 (d) to obtain 2.20 g (yield 84%) of the title compound as an oily substance. . IRνcm -1 : 2920, 2850, 1450. NMR (CDCl 3 ) δ: 0.70-1.20 (13H, m), 2.26 (6H, s), 2.00-3.50 (11H, m). This was recrystallized as dihydrochloride from ethanol/ether to give 0.80 g of colorless needles with a melting point of 98-100℃.
(yield 31%). Elemental analysis value C 14 H 32 Cl 2 N 2 S (assuming molecular weight 317.40) Calculated value C: 52.98, H: 10.16, N: 8.83 Actual value C: 53.10, H: 10.00, N: 8.66 Example 3 4-(2 -diethylaminoethyl)-2-hexylthiomorpholine Processed in the same manner as in Example 1 (d) using 2.00 g (0.0106 mol) of 2-hexylthiomorpholine and 2.02 g (0.0117 mol) of β-diethylaminoethyl chloride hydrochloride. to produce the title compound as a yellow oil.
2.14 g (yield 70%) was obtained. IRνcm -1 : 2920, 2850, 2800, 1450. NMR (CDCl 3 ) δ: 0.70-1.50 (13H, m), 1.06 (6H, t, J = 7.0Hz), 2.10-3.25 (11H, m), 2.60 (4H, q, J = 7.0Hz). This was converted into dihydrochloride and recrystallized from ethanol/ether as colorless needle crystals with a melting point of 197-201℃.
1.40g (yield 37%) was obtained. Elemental analysis value C 16 H 36 Cl 2 N 2 S (as molecular weight 359.61) Calculated value C: 53.44, H: 10.09, N: 7.79 Actual value C: 53.13, H: 9.99, N: 7.50 Example 4 4-(2 -diisopropylaminoethyl)-2-
Production of hexylthiomorpholine 2.00 g (0.0106 mol) of 2-hexylthiomorpholine and 2.350 g (0.0117 mol) of β-diisopropylaminoethyl chloride hydrochloride were treated in the same manner as in Example 1 (d) to give the title compound a yellow color. 2.88 g (yield 88%) was obtained as an oily substance. IRνcm -1 : 2950, 2920, 2850, 2800, 1455. NMR (CDCl 3 ) δ: 0.70-1.60 (13H, m), 1.00 (12H, d, J = 6.0Hz), 2.10-3.30 (13H, m) .. This was recrystallized from ethanol/ether as the dihydrochloride to give colorless prismatic crystals with a melting point of 180-184℃.
2.15g (yield 52%) was obtained. Elemental analysis value C 18 H 40 Cl 2 N 2 S (as molecular weight 387.51) Calculated value C: 55.79, H: 10.40, N: 7.23 Actual value C: 55.50, H: 9.98, N: 7.00 Example 5 4-(2 -diethylaminoethyl)-2-heptylthiomorpholine production (a) Nonanoyl chloride 25.00g (0.142 mol)
Add 27.16g (0.170mol) of bromine to
Stir for an hour. The reaction mixture was diluted with ethanol under ice-cooling, and the ethanol was distilled off under reduced pressure.
37.52 g (yield: 100%) of ethyl α-bromononanate was obtained as a yellow oil. IRνcm -1 : 2930, 2850, 1735, 1245. NMR (CDCl 3 ) δ: 0.70-1.60 (15H, m), 1.26 (3H, J = 7.0Hz), 1.80-2.25 (2H, m), 4.15 (1H , t, J = 6.0Hz), 4.21 (2H, q, J = 7.0Hz). (b) 37.52 g of the above ethyl α-bromononanate
(0.142 mol) was treated in the same manner as in Example 1 (b) to obtain 30.00 g (98% yield) of 2-heptylthiomorpholin-3-one as a colorless oil. IRνcm -1 : 1645 (-NHCO-) NMR (CDCl 3 ) δ: 0.70-1.70 (15H, m), 2.70-3.00 (2H, m), 3.25-3.80 (3H, m), 7.50 (1H,, bs ). (c) The above 2-heptylthiomorpholin-3-one
25.00 g (0.116 mol) was treated in the same manner as in Example 1 (c) to obtain 18.60 g (80% yield) of 2-heptylthiomorpholine as a colorless oil. IRνcm -1 : 3250, 2930, 2860, 1460. NMR (CDCl 3 ) δ: 0.70-1.60 (15H, m), 2.00 (1H, s), 2.40-3.70 (7H, m). (d) 2.00g of the above 2-heptylthiomorpholine
(0.0099 mol) and treated in the same manner as in Example 1 (d) to obtain 1.70 g of the title compound as a colorless oily substance.
(yield 57%). IRνcm -1 : 2990, 2950, 2880, 2820, 1480. NMR (CDCl 3 ) δ: 0.70-1.60 (15H, m), 1.00 (6H, t, J = 6.5Hz), 2.10-3.20 (11H, m) , 2.52 (4H, q, J = 6.5Hz). This was recrystallized as a dihydrochloride salt from ethanol:ether to obtain 0.96 g (26% yield) of colorless needles with a melting point of 182-189°C. Elemental analysis value C 17 H 38 Cl 2 N 2 S (as molecular weight 373.48) Calculated value C: 54.67, H: 10.26, N: 7.50 Actual value C: 54.37, H: 10.00, N: 7.39 Example 6 4-(2 -dimethylaminoethyl)-2-octylthiomorpholine (a) Using 25.00 g (0.131 mol) of caprylic chloride instead of nonanoyl chloride in Example 5 (a), the same treatment was carried out to produce ethyl α-bromodeca. 35.00 g (quantitative) of nate was obtained as a yellow oily substance. IRνcm -1 : 2920, 2850, 1730, 1250, 1140. NMR (CDCl 3 ) δ: 0.80−2.15 (17H, m), 1.31 (3H, t, J=7.0Hz), 4.17 (1H, t,
J = 6.0Hz), 4, 24 (2H, q, J = 7.0Hz). (b) 35.00g of the above ethyl α-bromodecanate
(0.131 mol) was treated in the same manner as in Example 1 (b) to obtain 29.60 g (98% yield) of 2-octylthiomorpholin-3-one as a yellow oil. IRνcm -1 : 1660 (-NHCO-) NMR (CDCl 3 ) δ: 0.70-1.60 (17H, m), 2.70-3.00 (2H, m), 3.28-3.80 (3H, m), 7.10 (1H, bs) .. (c) The above 2-octylthiomorpholin-3-one
29.60 g (0.129 mol) was treated in the same manner as in Example 1 (c) to obtain 19.52 g (yield 70%) of 2-octylthiomorpholine as a colorless oil. IRνcm -1 : 2920, 2860, 1460. NMR (CDCl 3 ) δ: 0.70-1.60 (17H, m), 2.00 (1H, s), 2.45-3.90 (7H, m). (d) 2-octylthiomorpholine obtained above 1.50
g (0.0069 mol) was treated in the same manner as in Example 1 (d) to obtain 1.56 g (yield 78%) of the title compound as a colorless oil. IRνcm -1 : 2920, 2850, 1450. NMR (CDCl 3 ) δ: 0.70-1.60 (17H, m), 2.20 (6H, s), 2.46 (4H, s), 2.10- 3.20 (7H, m). This was converted into dihydrochloride and recrystallized from ethanol:ether to give colorless needle-like crystals with a melting point of 241-245°C.
g (yield 38%) was obtained. Elemental analysis value C 18 H 40 Cl 2 N 2 S (as molecular weight 387.82) Calculated value C: 53.46, H: 10.10, N: 7.79 Actual value C: 53.40, H: 9.98, N: 7.49 Example 7 4-(2 -diethylaminoethyl)-2-octylthiomorpholine Production 2.00 g of 2-octylthiomorpholine in place of 2-hexylthiomorpholine in Example 3
(0.0093 mol) was treated in the same manner to obtain 1.87 g (yield: 64%) of the title compound as a colorless oil. IRνcm -1 : 2960, 2930, 2850, 2800, 1460. NMR (CDCl 3 ) δ: 0.70-1.00 (3H, m), 1.02 (6H, t, J = 7.0Hz), 1.26 (14H, bs), 2.00 -3.7 (11H, m), 2.65 (4H, q, J = 7.0Hz). This was recrystallized as dihydrochloride from ethanol/ether to form colorless needle crystals with a melting point of 167-170℃.
1.22g (yield 34%) was obtained. Elemental analysis value C 18 H 40 Cl 2 N 2 S (as molecular weight 387.82) Calculated value C: 55.75, H: 9.88, N: 7.22 Actual value C: 55.60, H: 9.60, N: 7.00 Example 8 4-(2 -diisopropylaminoethyl)-2-
Production of octylthiomorpholine 2.000 g of 2-octylthiomorpholine in place of 2-hexylthiomorpholine in Example 4
(0.0093 mol) was treated in the same manner as in Example 4 to obtain 2.16 g of the title compound as a colorless oily substance.
(yield 90%). IRνcm -1 : 2950, 2910, 2850, 2790, 1470. NMR (CDCl 3 ) δ: 0.80-1.60 (17H, m), 1.02 (12H, d, J = 6.0Hz), 2.10-3.30 (13H, m) .. This was converted into dihydrochloride and recrystallized from ethanol:ether to obtain colorless needle crystals with a melting point of 175-178°C.
g (yield 16%) was obtained. Elemental analysis value C 20 H 44 Cl 2 N 2 S (as molecular weight 415.56) Calculated value C: 57.80, H: 10.67, N: 6.74 Actual value C: 57.50, H: 10.29, N: 6.49 Example 9 4-(2 -diethylaminoethyl)-2-nonylthiomorpholine production (a) 9.41 g of undecanoyl chloride instead of nonanoyl chloride in Example 5 (a)
(0.0460 mol) was treated in the same manner as above to obtain 13.47 g (yield: 100%) of ethyl α-bromodecanate as a yellow oily substance. IRνcm -1 : 2920, 2850, 1730, 1260, 1140. NMR (CDCl 3 ) δ: 0.70-1.10 (3H, m), 1.30 (14H, bs), 1.31 (3H, t, J = 7.0Hz), 1.80 -2.20 (2H, m), 4.18 (1H, t, J = 6.0Hz), 4.24 (2H, q, J = 7.0Hz). (b) 13.47g of the above ethyl α-bromodecanate
(Using 0.0460 mol, according to Example 1 (b), 2-
11.00 g (yield 98%) of nonylthiomorpholin-3-one was obtained as a colorless oil. IRνcm -1 : 1655 (-NHCO-) NMR (CDCl 3 ) δ: 0.70-1.10 (3H, m), 1.30 (16H, bs), 2.75-3.00 (2H, m), 3.29-3.80 (3H, m) , 7.15 (1H, bs). (c) The above 2-nonylthiomorpholin-3-one
4.00 g (0.045 mol) was treated in the same manner as in Example 1 (c) to obtain 7.04 g (66% yield) of 2-nonanylthiomorpholine as a colorless oil. IRνcm -1 : 3250, 2930, 2855, 1460. NMR (CDCl 3 ) δ: 0.70-1.05 (3H, m), 1.25 (16H, m), 2.30-3.65 (8H, m). (d) 2.00g of the above 2-nonanylthiomorpholine
(0.0087 mol) and treated in the same manner as in Example 3 to obtain 2.14 g of the title compound as a colorless oil.
(yield 57%). IRνcm -1 : 2960, 2930, 2840, 1460. NMR (CDCl 3 ) δ: 0.70-1.05 (3H, m), 1.00 (6H, t, J = 7.0Hz), 1.25 (16H, bs), 2.10 (- 3.30 (7H, m), 2.50 (4H, s). This was made into a dihydrochloride salt and recrystallized from ethanol:ether to give 1.13 g of colorless needle crystals with a melting point of 162-170°C.
(yield 32%). Elemental analysis value C 19 H 42 Cl 2 N 2 S (as molecular weight 40.54) Calculated value C: 56.83, H: 10.54, N: 6.98 Actual value C: 56.59, H: 10.22, N: 6.59 Example 10 4-(2 -diisopropylaminoethyl)-2-
Production of nonylthiomorpholine 2.00 g of 2-nonylthiomorpholine was used instead of 2-hexylthiomorpholine in Example 4.
(0.0087 mol) was treated in the same manner to obtain 2.56 g (yield: 83%) of the title compound as a colorless oil. IRνcm -1 : 2950, 2920, 2850, 2800, 1665, 1455. NMR (CDCl 3 ) δ: 0.70-1.60 (19H, m), 1.02 (12H, d, J = 6.0Hz), 2.10-3.25 (11H, m). This was converted into dihydrochloride and recrystallized from ethanol:ether as colorless needle crystals with a melting point of 154-165℃.
1.64g (yield 44%) was obtained. Elemental analysis value C 21 H 46 Cl 2 N 2 S (as molecular weight 429.59) Calculated value C: 58.71, H: 10.79, N: 6.52 Actual value C: 58.60, H: 10.66, N: 6.40 Example 11 2-decyl- Production of (2-dimethylaminoethyl)thiomorpholine (a) 22.00 g of dodecanoyl chloride instead of nonanoyl chloride in Example 5 (a)
(0.1006 mol) was treated in the same manner as above to obtain 30.70 g (quantitative) of ethyl α-bromodecanate as a yellow oily substance. IRνcm -1 : 2930, 2850, 1735, 1255, 1145. NMR (CDCl 3 ) δ: 0.70-1.60 (19H, m), 1.31 (3H, t, J = 7.0Hz), 1.85-2.40 (2H, m) , 4.17 (1H, t, J = 6.0Hz), 4.24 (2H, q, J = 7.0Hz). (b) 30.70g of the above ethyl α-bromododecanate
2-decylthiomorpholin-3-one was recrystallized from ether:hexane using 0.1006 mol of 2-decylthiomorpholin-3-one, melting point 56-57.
24.40g (yield 94%) as colorless prism crystals at °C
I got it. IRνcm -1 : 1660 (-NHCO-) NMR (CDCl 3 ) δ: 0.70-1.70 (21H, m), 2.70-3.00 (2H, m), 3.25-3.75 (3H, m), 6.80 (1H, bs) .. (c) The above 2-decylthiomorpholin-3-one
20.00 g (0.0777 mol) was treated in the same manner as in Example 1 (c) to obtain 14.76 g (78% yield) of 2-decylthiomorpholine as a colorless oil. IRνcm -1 : 3250, 2920, 2850, 1455. NMR (CDCl 3 ) δ: 0.70−1.80 (22H, m), 2.40−3.35 (76H, m). (d) 2.00g of the above 2-decylthiomorpholine
(0.0082 mol) and treated in the same manner as in Example 1 (d) to obtain 1.26 g of the title compound as a colorless oily substance.
(yield 49%). IRνcm -1 : 2920, 2850, 1450. NMR (CDCl 3 ) δ: 0.70−1.60 (21H, m), 2.27 (6H, s), 2.15−3.30 (11H, m). This was converted into dihydrochloride and recrystallized from ethanol:ether to give colorless prismatic crystals with a melting point of 134-135℃.
1.05g (yield 33%) was obtained. Elemental analysis value C 18 H 40 Cl 2 N 2 S (as molecular weight 387.51) Calculated value C: 55.79, H: 10.40, N: 7.23 Actual value C: 55.66, H: 10.20, N: 7.00 Example 12 2-decyl- 4-(2-diethylaminoethyl)
Production of thiomorpholine 2.00 g of 2-decylthiomorpholine was used instead of 2-hexylthiomorpholine in Example 3.
(0.0082 mol) was treated in the same manner to obtain 2.450 (yield: 86%) of the title compound as a colorless oil. IRνcm -1 : 2960, 2920, 2850, 2800, 1460. NMR (CDCl 3 ) δ: 0.70-1.55 (21H, m), 1.03 (6H, t, J = 7.0Hz), 2.10-3.20 (11H, m) , 2.55 (4H, q, J = 7.0Hz). This was converted into dihydrochloride and recrystallized from ethanol:ether to give colorless prismatic crystals with a melting point of 193-197℃.
0.600 g (yield 18%) was obtained. Elemental analysis value C 20 H 44 Cl 2 N 2 S (as molecular weight 415.56) Calculated value C: 57.81, H: 10.67, N: 6.74 Actual value C: 57.80, H: 10.62, N: 7.01 Example 13 2-decyl- Production of 4-(2-diisopropylaminoethyl)thiomorpholine 2.00 g of 2-decylthiomorpholine in place of 2-hexylthiomorpholine in Example 4
(0.0082 mol) and treated in the same manner to obtain 2.90 g of the title compound as a colorless oil (yield: 95
%) was obtained. IRνcm -1 : 2960, 2930, 2850, 2800, 1460. NMR (CDCl 3 ) δ: 0.70-1.60 (21H, m), 1.01 (12H, d, J = 6.0Hz), 2.10-3.25 (13H, m) .. This was made into a dihydrochloride salt and recrystallized from ethanol:ether to obtain 2.33 g (68% yield) of colorless prism crystals with a melting point of 176-178°C. Elemental analysis value C 22 H 48 Cl 2 N 2 S (as molecular weight 443.62) Calculated value C: 59.57, H: 10.91, N: 6.31 Actual value C: 58.99, H: 10.59, N: 6.01 Example 14 4-(2 -diethylaminoethyl)-2-undecylthiomorpholine production (a) Using 20.00 g (0.0933 mol) of tridecanoic acid instead of n-caproic acid in Example 1 (a),
The same process was repeated to obtain 29.97g of ethyl α-bromotridecanate as a yellow oil (yield: 100g).
%) was obtained. IRνcm -1 : 2930, 2850, 1730, 1260, 1155. NMR (CDCl 3 ) δ: 0.70−1.05 (3H, m), 1.29 (18H, bs), 1.30 (3H, t, J = 7.0Hz), 1.80 -2.30 (2H, m), 4.17 (1H, t, J = 6.0Hz), 4.22 (2H, q, J =
7.0Hz). (b) The above ethyl α-bromotridecanate 29.97
g (0.0933 mol) and treated in the same manner as in Example 1 (b) to obtain 2-undecylthiomorpholine-3-
24.66g (yield 97%) of on as a colorless oily substance
I got it. IRνcm -1 : 1660 (-NHCO-) NMR (CDCl 3 ) δ: 0.70-1.10 (3H, m), 1.28 (20H, bs), 2.70-3.00 (2H, m), 3.28-3.71 (3H, m) , 7.15 (1H, bs). (c) 20.00 g (0.0734 mol) of the above 2-undecylthiomorpholin-3-one was treated in the same manner as in Example 1 (c) to obtain 17.21 g (yield) of 2-undecylthiomorpholine as a colorless oil. 91%). IRνcm -1 : 2250, 2920, 2850, 1460. NMR (CDCl 3 ) δ: 0.70−1.10 (3H, m), 1.27 (20H, bs) 1.85 (1H, bs), 2.30−3.45 (7H, m). (d) 2.00g of the above 2-undecylthiomorpholine
(0.0077 mol) and treated in the same manner as in Example 3 to obtain 1.73 g of the title compound as a colorless oil.
(yield 63%). IRνcm -1 : 2960, 2930, 2850, 2800, 1460. NMR (CDCl 3 ) δ: 0.75-1.10 (3H, m), 1.06 (6H, t, J = 7.0Hz), 1.25 (20H, bs), 2.10 −3.20 (15H, m). This was recrystallized as a dihydrochloride from ethanol:ether to obtain 0.650 g (70% yield) of colorless prism crystals with a melting point of 175-183°C. Elemental analysis value C 21 H 46 Cl 2 N 2 S (as molecular weight 429.59) Calculated value C: 58.72, H: 10.79, N: 6.52 Actual value C: 58.55, H: 10.68, N: 6.50 Example 15 4-(2 -diisopropylaminoethyl)-2-
Production of undecylthiomorpholine 2.00 g of 2-undecylthiomorpholine was used instead of 2-hexylthiomorpholine in Example 4.
(0.0077 mol) was treated in the same manner to obtain 2.54 g (yield: 86%) of the title compound as a colorless oil. IRνcm -1 : 2960, 2920, 2850, 2800, 1460. NMR (CDCl 3 ) δ: 0.70-1.60 (23H, m), 1.00 (12H, d, J = 6.0Hz), 2.00-2.30 (13H, m) .. This was converted into dihydrochloride and recrystallized from ethanol:ether to obtain colorless prismatic crystals with a melting point of 162-168℃.
1.21 g (yield 34%) was obtained. Elemental analysis value C 23 H 50 Cl 2 N 2 S (as molecular weight 457.65) Calculated value C: 60.36, H: 11.01, N: 6.12 Actual value C: 60.12, H: 10.98, N: 5.98 Example 16 4-(2 -dimethylaminoethyl)-2-dodecylthiomorpholine production (a) 26.00 g of tetradecanoyl chloride instead of nonanoyl chloride in Example 5 (a)
(0.1053 mol) was treated in the same manner to obtain 35.30 g (quantitative) of ethyl α-bromotetradecanate as a yellow oil. IRνcm -1 : 2920, 2850, 1735, 1255, 1160. NMR (CDCl 3 ) δ: 0.70-1.60 (23H, m), 1.31 (3H, t, J = 7.0Hz), 1.80-2.40 (2H, m) , 4.20 (1H (1H, t, J = 6.0Hz), 4.25 (2H, q, J = 7.0Hz). (b) 35.30 g of the above ethyl α-bromodecanate
(0.1053 mol was used and treated in the same manner as in Example 1 (b) to obtain 2-dodecylthiomorpholin-3-one, which was recrystallized from ether:hexane as colorless prism crystals with a melting point of 68-69°C. 30.30g
(yield 100%). IRνcm -1 : 1655 (-NHCO-) NMR (CDCl 3 ) δ: 0.70-1.00 (3H, m), 1.26 (22H, bs), 2.70-3.00 (2H, m), 3.20-3.80 (3H, m) , 6.55 (1H, bs). (c) 20.00g of the above 2-dodecylthiomorpholine
(0.070 mol) was treated in the same manner as in Example 1 (c) to obtain 16.80 g (yield: 88%) of 2-dodecylthiomorpholine as a colorless oil. IRνcm -1 : 3200, 2910, 2840, 1460. NMR (CDCl 3 ) δ: 0.70-1.00 (3H, m), 1.25 (22H, bs), 2.20 (1H, s) 2.45-3.75 (7H, m). (d) 2-dodecylthiomorpholine obtained above 2.00
g (0.0074 mol) and treated in the same manner as in Example 2 (d) to obtain the title compound as a colorless oil with 1.32
g (yield 74%). IRνcm -1 : 2930, 2850, 1455. NMR (CDCl 3 ) δ: 0.70−1.60 (25H, m), 2.23 (6H, s), 2.01−3.25 (11H, m). Recrystallize this as dihydrochloride from ethanol:ether to give 1.00 g of colorless needles with a melting point of 137-140℃.
(yield 33%). Elemental analysis value C 20 H 44 Cl 2 N 2 S (as molecular weight 415.56) Calculated value C: 57.81, H: 10.67, N: 6.74 Actual value C: 57.60, H: 10.42, N: 6.50 Example 17 4-(2 -diethylaminoethyl)-2-dodecylthiomorpholine production 2.00 g of 2-dodecylthiomorpholine in place of 2-hexylthiomorpholine in Example 3
(0.0074 mol) was treated in the same manner to obtain 2.20 g (yield 77%) of the title compound as a colorless oil. IRνcm -1 : 2960, 2930, 2850, 2800, 1465. NMR (CDCl 3 ) δ: 0.70-1.60 (25H, m), 1.06 (6H, t, J = 7.0Hz), 2.10-3.20 (15H, m) .. This was converted into dihydrochloride and recrystallized from ethanol:ether as colorless needle crystals with a melting point of 156-161℃.
1.120 g (yield 33%) was obtained. Elemental analysis value C 22 H 48 Cl 2 N 2 S (as molecular weight 443.62) Calculated value C: 59.57, H: 10.91, N: 6.31 Actual value C: 59.30, H: 10.80, N: 6.00 Example 18 4-(2 -diisopropylaminoethyl)-2-
Production of dodecylthiomorpholine 2.00 g of 2-dodecylthiomorpholine was used instead of 2-hexylthiomorpholine in Example 4.
(0.0074 mol) was treated in the same manner to obtain 2.12 g (yield 72%) of the title compound as a colorless oil. IRνcm -1 : 2960, 2930, 2850, 2800, 1460. NMR (CDCl 3 ) δ: 0.70-1.65 (25H, m), 1.00 (12H, t, J = 6.0Hz), 2.10-3.40 (15H, m) .. This was converted into dihydrochloride and recrystallized from ethanol/ether to produce colorless prismatic crystals with a melting point of 168-171℃.
1.45g (yield 49%) was obtained. Elemental analysis value C 24 H 52 Cl 2 N 2 S (as molecular weight 471.67) Calculated value C: 61.12, H: 11.11, N: 5.94 Actual value C: 61.00, H: 10.98, N: 5.66 Example 19 4-(2 -dimethylaminoethyl)-2-tridecylthiomorpholine (a) Using 20.00 g (0.0825 mol) of pentadecanoic acid in place of n-caproic acid in Example 1 (a),
27.80g (quantitative) of ethyl α-bromopentadecanate was obtained as a yellow oil by the same treatment.
I got it. IRνcm -1 : 2920, 2860, 1740, 1260, 1165. NMR (CDCl 3 ) δ: 0.70−1.05 (3H, m), 1.30 (3H, t, J = 7.0Hz), 1.26 (20H, bs), 1.85 -2.20 (2H, m), 4.19 (1H, t, J = 6.0Hz), 4.25 (2H, q, J = 7.0Hz). (b) Using 27.80 g (0.0825 mol) of ethyl α-bromopentadecanate obtained above, Example 1 (b)
2-tridecylthiomorpholin-3-one was obtained in the same manner as 2-tridecylthiomorpholin-3-one, which was recrystallized from ether:hexane to obtain 20.49 g (87% yield) of colorless prismatic crystals with a melting point of 65-66°C. . IRνcm -1 : 1650 (-NHCO-) NMR (CDCl 3 ) δ: 0.70-1.05 (3H, m), 1.25 (24H, bs), 2.69-2.95 (2H, m), 3.20-3.70 (3H, m) , 6.65 (1H, bs). (c) The above 2-tridecylthiomorpholine-3-
Example 1 using 23.50 g (0.0825 mol) of
17.68g of 2-tridecylthiomorpholine was obtained as a colorless oil (yield: 75%) in the same manner as in (c).
I got it. IRνcm -1 : 3250, 2930, 2850, 1450. NMR (CDCl 3 ) δ: 0.70-1.80 (27H, m), 2.40-3.35 (7H, m). (d) 2.00 g of the above 2-tridecylthiomorpholine
(0.0070 mol) and treated in the same manner as in Example 2 (d) to obtain 1.75 g of the title compound as a colorless oily substance.
(yield 72%). IRνcm -1 : 2920, 2850, 1450. NMR (CDCl 3 ) δ: 0.70-1.60 (27H, m), 2.26 (6H, s), 2.15-3.32 (11H, m). Recrystallize this as dihydrochloride from ethanol:ether to give 0.960 g of colorless needles with a melting point of 88-92℃.
(yield 32%). (No elemental analysis due to endothermic property) Example 20 Production of 4-(2-diethylaminoethyl)-2-tridecylthiomorpholine 2.00 g of 2-dodecylthiomorpholine in place of 2-hexylthiomorpholine in Example 3
(0.0070 mol) was treated in the same manner to obtain 1.56 g (yield 59%) of the title compound as a colorless oil. IRνcm -1 : 2970, 2940, 2860, 2820, 1465. NMR (CDCl 3 ) δ: 0.70-1.05 (3H, m), 1.02 (6H, t, J = 7.0Hz), 1.26 (24H, bs), 2.10 -3.2 (11H, m), 2.58 (4H, q, J = 7.0Hz). This was converted into a dihydrochloride salt and recrystallized from ethanol:ether to obtain 0.860 g (yield 27%) of colorless needle crystals with a melting point of 176-183°C. Elemental analysis value C 23 H 50 Cl 2 N 2 S (as molecular weight 475.65) Calculated value C: 60.36, H: 11.01, N: 6.12 Actual value C: 60.11, H: 10.92, N: 5.98 Example 21 4-(2 -diisopropylaminoethyl)-2-
Production of tridecylthiomorpholine 2.00 g of 2-tridecylthiomorpholine in place of 2-hexylthiomorpholine in Example 4
(0.0070 mol) was treated in the same manner to obtain 2.32 g (yield: 80%) of the title compound as a colorless oil. IRνcm -1 : 2960, 2930, 2850, 2800, 1460. NMR (CDCl 3 ) δ: 0.70−1.10 (3H, m), 1.03 (12H, d, J = 6.0Hz), 1.28 (24H, bs), 2.10 −3.25 (13H, m). This was made into a dihydrochloride salt and recrystallized from ethanol:ether to obtain 1.50 g (44% yield) of colorless prism crystals with a melting point of 168-171°C. Elemental analysis value C 25 H 54 Cl 2 N 2 S (assuming molecular weight 485.70) Calculated value C: 61.82, H: 11.21, N: 5.77 Actual value C: 61.66, H: 11.01, N: 5.42 Example 22 4-(2 -diethylaminoethyl)-2-tetradecylthiomorpholine (a) 25.00 g (0.09
mol) and treated in the same manner to obtain ethyl α-bromohexadecanate as a yellow oil.
33.80g (quantitative) was obtained. IRνcm -1 : 2920, 2850, 1730, 1255, 1140. NMR (CDCl 3 ) δ: 0.70−1.05 (3H, m), 1.28 (26H, bs) 1.30 (1H, t, J = 7.0Hz), 1.80− 2.30 (2H, m), 4.13 (1H, t, J = 6.0Hz), 4.21 (2H, q, J =
7.0Hz). (b) The above ethyl α-bromohexadecanate
Using 33.80 g (0.091 mol), the same procedure as in Example 1 (b) was used to obtain 26.80 g (yield 94%) of 2-tetradecylthiomorpholin-3-one as a colorless oil. IRνcm -1 : 1660 (-NHCO-) NMR (CDCl 3 ) δ: 0.70-1.10 (3H, m), 1.30 (26H, bs), 2.71-3.00 (2H, m), 3.10-3.75 (3H, m) , 7.10 (1H, bs). (c) The above 2-tetradecylthiomorpholine-3-
2-
16.25 g (yield: 85%) of tetradecylthiomorpholine was obtained as a colorless oil. IRνcm -1 : 2960, 2930, 2860, 2820, 1465. NMR (CDCl 3 ) δ: 0.70-1.00 (3H, m), 1.25 (26H, bs), 1.85 (1H, s), 2.20-3.70 (7H, m). (d) 2.00g of the above tetradecylthiomorpholine
(0.0067 mol) and treated in the same manner as in Example 1 (d) to obtain 1.56 g of the title compound as a colorless oily substance.
(yield 59%). IRνcm -1 : 2960, 2900, 2850, 2800, 1460. NMR (CDCl 3 ) δ: 0.70−1.00 (3H, m), 1.05 (6H, t, J = 7.0Hz), 1.25 (26H, bs), 2.01 -3.20 (11H, m), 2.57 (4H, q, J = 7.0Hz). This was recrystallized as a dihydrochloride from ethanol:acetone to obtain 0.550 g (yield 17%) of colorless prism crystals with a melting point of 158-165°C. Elemental analysis value C 24 H 52 Cl 2 N 2 S (as molecular weight 471.67) Calculated value C: 61.12, H: 11.11, N: 5.94 Actual value C: 60.90, H: 10.79, N: 5.80 Example 23 4-(2 -diethylaminoethyl)-2-pentadecylthiomorpholine production (a) Using 20.00 g (0.074 mol) of heptadecanoic acid instead of n-caproic acid in Example 1 (a),
27.00g (quantitative) of ethyl α-bromoheptadecanate was obtained as a yellow oil by the same treatment.
I got it. IRνcm -1 : 2920, 2850, 1735, 1250, 1140. NMR (CDCl 3 ) δ: 0.70−1.05 (3H, m), 1.25 (26H, bs), 1.30 (3H, t, J = 7.0Hz), 1.80 -2.15 (1H, m), 4.15 (1H, t, J = 6.0Hz), 4.22 (2H, q, J = 7.0Hz). (b) The above ethyl α-bromoheptadecanate
27.00 g (0.0740 mol) was treated in the same manner as in Example 1 (b) to obtain 2-pentadecylthiomorpholin-3-one, which was recrystallized from ether:hexane to give colorless prisms with a melting point of 68-69°C. as crystal
22.00g (yield 96%) was obtained. IRνcm -1 : 1655 (-NHCO-) NMR (CDCl 3 ) δ: 0.70-1.05 (3H, m), 1.26 (28H, bs), 2.60-3.00 (2H, m), 3.20-3.70 (3H, m) , 6.50 (1H, bs). (c) The above 2-pentadecylthiomorpholine-3-
Example 1 (c) using 20.000 g (0.0642 mol) of
14.40g of 2-pentadecylthiomorpholine was obtained as a colorless oil (yield 72%).
I got it. IRνcm -1 : 2960, 2920, 2850, 2800, 1460. NMR (CDCl 3 ) δ: 0.70-1.00 (3H, m), 1.25 (26H, m), 1.85 (1H, s), 2.20-3.70 (7H, m). (d) The above 2-pentadecylthiomorpholine 2.00
g (0.0064 mol) was treated in the same manner as in Example 2 (d) to obtain 2.03 g (yield 77%) of the title compound as a colorless oil. IRνcm -1 : 2960, 2900, 2840, 2800, 1450. NMR (CDCl 3 ) δ: 0.70−1.05 (3H, m), 1.06 (6H, t, J = 7.0Hz), 1.25 (28H, bs), 2.01 -3.20 (11H, m), 2.56 (4H, q, J = 7.0Hz). This was converted into dihydrochloride and recrystallized from ethanol:ether to obtain colorless prismatic crystals with a melting point of 180-186℃.
1.00 g (yield 32%) was obtained. (Elemental analysis not performed due to endothermic property) Example 24 Production of 4-(2-diethylaminoethyl)-2-pentadecylthiomorpholine 2.00% of 2-pentadecylthiomorpholine was used in place of 2-hexylthiomorpholine in Example 3. g
(0.0064 mol) was treated in the same manner to obtain 2.03 g (yield 77%) of the title compound as a colorless oil. IRνcm -1 : 2960, 2930, 2850, 2800, 1460. NMR (CDCl 3 ) δ: 0.70-1.05 (3H, m), 1.01 (6H, t, J = 7.0Hz), 1.25 (28H, bs), 2.20 -3.20 (11H, m), 2.50 (4H, q, J = 7.0Hz). This was recrystallized as a dihydrochloride salt from ethanol:ether to obtain 1.00 g (yield: 32%) of colorless prism crystals with a melting point of 180-186°C. Elemental analysis value C 25 H 54 Cl 2 N 2 S (as molecular weight 485.70) Calculated value C: 61.82, H: 11.21, N: 5.77 Actual value C: 61.50, H: 10.98, N: 5.60 Example 25 4-(2 -diisopropylaminoethyl)-2-
Production of pentadecylthiomorpholine 2.00 g of 2-pentadecylthiomorpholine in place of 2-hexylthiomorpholine in Example 4
(0.0064 mol) was treated in the same manner to obtain 2.13 g (yield 76%) of the title compound as a colorless oil. IRνcm -1 : 3020, 2955, 1460. NMR (CDCl 3 ) δ: 0.98 (12H, d, J=6.0Hz) 0.70−1.50 (31H, m), 2.00−3.20 (11H, m). This was converted into dihydrochloride and recrystallized from ethanol:ether to obtain colorless prismatic crystals with a melting point of 168-171℃.
1.98g (yield 71%) was obtained. Elemental analysis value C 27 H 56 Cl 2 N 2 S (as molecular weight 511.74) Calculated value C: 63.37, H: 11.03, N: 5.47 Actual value C: 63.05, H: 10.98, N: 5.20 Example 26 4-(2 -diethylaminoethyl)-2-heptadecylthiomorpholine (a) Using 5.00 g (0.0167 mol) of nonadecanoic acid in place of n-caproic acid in Example 1 (a), the same treatment was performed to obtain ethyl α-bromo 6.59 g (quantitative) of nonadecanate was obtained as a yellow oil. IRνcm -1 : 2930, 2860, 1740, 1260, 1150. NMR (CDCl 3 ) δ: 0.70−1.10 (3H, m), 1.28 (28H, bs), 1.80−2.25 (2H, m), 4.16 (1H, t, J = 6.0Hz), 4.23 (2H, q, J = 7.0Hz). (b) The above ethyl α-bromononadecanate 5.00
g (0.0127 mol) and treated in the same manner as in Example 1 (b) to obtain 2-heptadecylthiomorpholine-3.
-on was obtained, which was recrystallized from chloroform:n-hexane to give 3.55 g of colorless needles with a melting point of 83°C.
(yield 82%). IRνcm -1 : 1650 (-NHCO-) NMR (CDCl 3 ) δ: 0.70-1.10 (3H, m), 1.28 (32H, bs), 2.65-3.05 (2H, m), 3.20-3.70 (3H, m) , 7.00 (1H, m). (c) The above 2-heptadecylthiomorpholine-3
Example 1 using 2.60 g (0.0073 mol) of
2.50g of 2-heptadecylthiomorpholine was obtained as a colorless oil (yield 100g) in the same manner as in (c).
%) was obtained. IRνcm -1 : 3250, 2930, 2550, 1460. NMR (CDCl 3 ) δ: 0.70-1.00 (3H, m), 1.26 (32H, bs) 1.70 (1H, s), 2.20-3.60 (7H, m). (d) The above 2-heptadecylthiomorpholine 2.000
g (0.0058 mol) and treated in the same manner as in Example 3 to obtain 1.85 g of the title compound as a colorless oil.
(yield 72%). IRνcm -1 : 2960, 2930, 2850, 2800 1460. NMR (CDCl 3 ) δ: 0.65−1.00 (3H, m), 1.04 (6H, t, J = 7.0Hz), 1.28 (32H, bs), 2.20− 3.20 (15H, m). This was converted into dihydrochloride and recrystallized from ethanol:ether as colorless needle crystals with a melting point of 194-197℃.
1.05g (yield 36%) was obtained. Elemental analysis value C 27 H 58 Cl 2 N 2 S (as molecular weight 513.76) Calculated value C: 63.12, H: 10.99, N: 5.45 Actual value C: 62.99, H: 10.69, N: 5.18 Compound of the present invention and its physiological properties The salts acceptable for this have excellent coronary vasodilator effect, platelet aggregation inhibiting effect, anti-peptic ulcer effect, etc., and are useful as medicines. The pharmacological actions of representative compounds of the present invention will be explained below. 1. Platelet aggregation inhibitory effect Blood is collected from the ear artery of a rabbit using sodium citrate as an anticoagulant. Platelet-rich plasma (PRP) and platelet-poor plasma (PPP) are obtained by centrifugal fractionation. PRP250μ with platelet count adjusted to 400,000/ mm2
was placed in a cuvette of an aggregometer (HUM type, manufactured by Rika Denki), and 1 mmol of calcium chloride was added while incubating at 37°C. After 1 minute, add an appropriate amount of the test compound. After another minute, 10 μmol of adenosine diphosphate (ADP), 38 μg/ml of collagen, or 0.3 mmol of arachidonic acid is added as a flocculant, and the change in light transmittance is measured using an aggregometer. The agglutination effect is the maximum agglutination of the control.
The inhibition rate was determined by setting the concentration as 100 and compared with the sample concentration (IC 50 μg/ml) that inhibits aggregation by 80%. The results are shown in the table below.
【表】【table】
【表】
2 冠血管拡張作用
ランゲルドルフ法の変化〔J.Pharmacol.
Method.2143〜156(1976)〕により検討した。す
なわちモルモツトの心臓の冠血管を38℃のクレブ
ス−ヘンセライト液(95%O2,5%CO2を通気)
で潅流し、その潅流圧を心臓への入口にて測定し
た。被検化合物は心臓への入口に設けたゴム管の
部分より0.1ml/heartの割合で、生理食塩水に溶
解して投与した。結果は塩酸パパベリン33μg/
heartによる反応を100%とし、それと比較し%で
表示した。結果は次表に示す通りで、本発明化合
物は塩酸パパベリンに比べて強くしかも持続性の
ある作用を示した。[Table] 2 Coronary vasodilatory effect Changes in the Langerdorf method [J.Pharmacol.
Method. 2 143-156 (1976)]. In other words, the coronary vessels of the guinea pig's heart were injected with Krebs-Henseleit solution (95% O 2 , 5% CO 2 aerated) at 38°C.
The perfusion pressure was measured at the entrance to the heart. The test compound was dissolved in physiological saline and administered at a rate of 0.1 ml/heart through a rubber tube provided at the entrance to the heart. The result is papaverine hydrochloride 33μg/
The response by heart was taken as 100%, and the comparison was expressed as a percentage. The results are shown in the table below, and the compound of the present invention showed stronger and longer lasting action than papaverine hydrochloride.
【表】【table】
【表】
3 抗消化性潰瘍作用
実験材料および方法
被検薬は0.9%生理食塩液に用時溶解して使用
した。
(1) ストレス潰瘍
24時間絶食した体重220〜260gのWistar系雄
ラツトを使用した。被検薬を経口投与30分後動物
をストレスケージに入れ、23℃の水槽内に胸部剣
状突起まで7時間水浸した後、動物をと殺し胃を
摘出した。胃内に生理食塩液10ml注入し、5%ホ
ルマリン液中で半固定した後胃を大湾に沿つて切
り開き、腺胃部に発生する個々の潰瘍の長径と短
径を実体顕微鏡(×10)にて測定し、その積を潰
瘍面積とし、個々の面積の総和を一匹あたりの潰
瘍係数(Ulcer indexU.I.)とした。その結果は
次表に示すように50mg/Kgの経口投与で対照に比
して約77%の抑制結果を示し100mg/Kgではほぼ
完全に潰瘍を抑えた。
投与量p.o. U.I. 抑制率%
対照 − 24.1±2.7 −
実施例21の化合物 50mg/Kg 5.6±2.4※
76.8
同上 100〃 1.1±0.8※
95.4
※P<0.01 v.s 対照
(2) インドメサシン潰瘍
24時間絶食した体重230〜280gのDonryu系雄
ラツトを使用した。被検薬を経口投与30分後、1
%CMC液に懸濁したインドメサシン30mg/Kgを
ラツトの皮下に投与し、7時間絶食絶水下に放置
した後、動物をと殺し胃を摘出し半固定した。そ
の後胃を開き、腺胃部に発生する黒かつ色の潰瘍
の長径を測定し、これを合計したものを一匹あた
りのU.I.値とした。その結果は次表に示すように
50〜100mg/Kgの経口投与で、ほぼ完全に潰瘍を
抑制する効果を示した。
投与量p.o. U.I. 抑制率%
対照 − 36.3±6.0 −
実施例21の化合物 50mg/Kg 0.9±0.9※
97.5
同上 100〃 2.4±1.2※
93.3
※P<0.01 v.s 対照[Table] 3 Anti-peptic ulcer effect Experimental materials and methods The test drug was dissolved in 0.9% physiological saline before use. (1) Stress ulcer Wistar male rats weighing 220 to 260 g that had been fasted for 24 hours were used. Thirty minutes after oral administration of the test drug, the animals were placed in stress cages and immersed in water up to the xiphoid process in a 23°C water tank for 7 hours, and then the animals were sacrificed and the stomachs were removed. After injecting 10 ml of physiological saline into the stomach and semi-fixing it in 5% formalin, the stomach was cut open along the greater bulge, and the major and minor axes of individual ulcers occurring in the glandular stomach were examined using a stereoscopic microscope (x10). The product was taken as the ulcer area, and the sum of the individual areas was taken as the ulcer index per animal (Ulcer index U.I.). As shown in the table below, oral administration of 50 mg/Kg resulted in about 77% inhibition compared to the control, and 100 mg/Kg suppressed ulcers almost completely. Dose po UI inhibition rate % Control - 24.1±2.7 - Compound of Example 21 50mg/Kg 5.6±2.4* 76.8 Same as above 100〃 1.1±0.8* 95.4 *P<0.01 vs Control (2) Indomethacin ulcer 24-hour fasted weight Donryu male rats weighing 230-280 g were used. 30 minutes after oral administration of the test drug, 1
30 mg/Kg of indomethacin suspended in a %CMC solution was administered subcutaneously to rats, and after being left without food or water for 7 hours, the animals were sacrificed, and the stomachs were removed and semi-fixed. Thereafter, the stomach was opened, and the long axis of the black and colored ulcer that occurred in the glandular stomach was measured, and the sum of these values was used as the UI value for each animal. The results are shown in the table below.
Oral administration of 50 to 100 mg/Kg showed almost complete ulcer suppression effects. Dose po UI inhibition rate % Control - 36.3±6.0 - Compound of Example 21 50mg/Kg 0.9±0.9* 97.5 Same as above 100〃 2.4±1.2* 93.3 *P<0.01 vs control
Claims (1)
−4−(2−アミノエチル)チオモルホリン化合
物およびその塩。 式中R1は炭素数3〜17個の直鎖アルキル基を
示し、R2は炭素数1〜4個の直鎖あるいは分枝
アルキル基を示す。[Scope of Claims] 1. A 2-alkyl-4-(2-aminoethyl)thiomorpholine compound represented by the following general formula [] and a salt thereof. In the formula, R 1 represents a straight chain alkyl group having 3 to 17 carbon atoms, and R 2 represents a straight chain or branched alkyl group having 1 to 4 carbon atoms.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP3535282A JPS58152875A (en) | 1982-03-06 | 1982-03-06 | 2-alkyl-4-(2-aminoethyl)thiomorpholine compound |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP3535282A JPS58152875A (en) | 1982-03-06 | 1982-03-06 | 2-alkyl-4-(2-aminoethyl)thiomorpholine compound |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS58152875A JPS58152875A (en) | 1983-09-10 |
| JPH036143B2 true JPH036143B2 (en) | 1991-01-29 |
Family
ID=12439467
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP3535282A Granted JPS58152875A (en) | 1982-03-06 | 1982-03-06 | 2-alkyl-4-(2-aminoethyl)thiomorpholine compound |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS58152875A (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006137335A1 (en) * | 2005-06-20 | 2006-12-28 | Otsuka Pharmaceutical Co., Ltd. | Process for producing piperazine derivative |
-
1982
- 1982-03-06 JP JP3535282A patent/JPS58152875A/en active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS58152875A (en) | 1983-09-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1265517A (en) | .alpha.-[2-OXO-2,4,5,6,7A-HEXAHYDRE-(3,2-C) THIENO-5-PYRIDYL] PHENYL ACETIC ACID DERIVATIVES; PROCESS FOR PREPARING THE SAME AND THEIR USE AS THERAPEUTIC AGENTS | |
| EP0201735B1 (en) | N-indolylethyl sulfon amides, process for their preparation and their use | |
| US4671901A (en) | Orally effective ion chelators | |
| JPS6121226B2 (en) | ||
| FR2514348A1 (en) | NOVEL CARBOXYLIC ACID SALTS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | |
| JPH0395154A (en) | (di-(tert.-butyl(hydroxy)phenylthio))-substituted hydroxamic acid derivative | |
| CH640824A5 (en) | ACYL-DERIVATIVES OF CARNITINE AND PROCEDURE FOR THEIR PREPARATION. | |
| CH644348A5 (en) | OXIDIZED AMINO-ETHERS, THEIR PREPARATION PROCESS AND THE MEDICAMENT CONTAINING THEM. | |
| Plapinger et al. | A Nitrogen-to-Oxygen Phosphoryl Migration: Preparation of dl-Serinephosphoric and Threoninephosphoric Acid | |
| EP0252823A1 (en) | 1H,3H-pyrrolo[1,2-c]thiazole derivatives, their preparation and pharmaceutical compositions containing them | |
| US4670469A (en) | Hydroxamic acid and pharmaceutical preparations containing the same | |
| EP0479631B1 (en) | Spiro[4,5]decane derivatives, process for their preparation and pharmaceutical compositions containing them | |
| Rabinowitz et al. | Some Pyrimidine Derivatives1 | |
| JPH036143B2 (en) | ||
| WO2001000621A1 (en) | Novel quaternary ammonium derivatives, method for preparing same and pharmaceutical use | |
| JPS6323857A (en) | Thio ester, manufacture and remedy for ischemic and reperfusion syndrome | |
| US5015664A (en) | Orally effective ion chelators related to deferoxamine | |
| Wilkinson et al. | The biological action of substances related to thyroxine. 4. The thyroxine-inhibitory properties of a series of 4-hydroxy-3: 5-diiodobenzoates of glycols | |
| JPS5943943B2 (en) | 1↓-phenyl↓-propanol derivative and its manufacturing method | |
| FR2460934A1 (en) | ISOQUINOLINE DERIVATIVES CONTAINING SULFUR, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | |
| US4611002A (en) | Carboxymethyl esters of mercaptopropanoic acids as enkephalinase inhibitors | |
| EA001959B1 (en) | New pentaerythritol derivatives, their production and use and intermediatesfor their synthesis | |
| EP0215319A2 (en) | Gem-dihalo-1,8-diamino-4-aza-octanes | |
| EP0395526B1 (en) | Benzothiazolinone derivatives, process for their preparation and pharmaceutical compositions containing them | |
| US3641097A (en) | Preparation of phenylalanine derivatives and novel intermediates |